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ABSTRACT 
Benjamin J. Privett: Sol-Gel-Derived Materials for Antimicrobial Coatings and 
Electrochemical Nitric Oxide Analysis 
(Under the direction of Professor Mark H. Schoenfisch) 
 
 Sol-gel-derived coatings modified to release nitric oxide (NO), an endogenous 
broad-spectrum antimicrobial, have been described as highly promising antimicrobial 
biomaterials. As part of my thesis work, I extended the study of the antimicrobial 
properties of NO-releasing xerogels against the adhesion, viability, and biofilm formation 
of the pathogenic fungus, Candida albicans. Nitric oxide fluxes as low as 14 pmol cm-2 s-
1 proved sufficient to reduce fungal adhesion by ~49% over controls (non-NO-releasing 
substrates) after 90 min of exposure. By utilizing a fluorescence live/dead assay and 
replicate plating, the NO flux was determined to reduce fungal viability in a dose-
dependent manner. Likewise, the formation of C. albicans biofilms on NO-releasing 
xerogel-coated silicon rubber (SiR) coupons was impeded when compared to control and 
bare SiR surfaces.  
To begin an examination of the likelihood of exogenous NO fostering NO 
resistance, bacteria were exposed to NO in long- and short-term mutagenesis assays. 
Even after 20 d of continuous sub-therapeutic exposure, resistance to NO was not 
observed for gram-positive and -negative species.  
The next phase of my research thus focused on the synthesis of superhydrophobic 
xerogel coatings from a mixture of nanostructured fluorinated silica colloids, 
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fluoroalkoxysilane, and a backbone silane. Quantitative bacterial adhesion studies 
performed using a parallel plate flow cell demonstrated that the adhesion of 
Staphylococcus aureus and Pseudomonas aeruginosa were reduced by 2.08 ± 0.25 and 
1.76 ± 0.12 log over controls, respectively. The straightforward and mild synthesis of this 
chemistry enables its application to any surface regardless of geometry making such 
interfaces ideal as biopassivation strategies. 
Along with NO’s ability to serve a potent exogenous antimicrobial, endogenous 
NO serves many important physiological roles (e.g., immune response, vasodilatation, 
neurotransmission). The final phase of my dissertation research focused on the 
development of microfluidic NO sensors capable of selectively measuring NO in small 
volumes (<1 mL). The final device enabled sensitive NO detection in PBS, blood, and 
simulated wound fluid at concentrations as low as 0.7–2.0 nM. Future studies using this 
device may prove useful clinically. 
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Chapter 1 
Introduction: Recent Advances in Antimicrobial Coatings, and  
Nitric Oxide Detection 
 
1.1 Antimicrobial coatings for biomedical applications 
As healthcare providers continue to innovate in the areas of disease diagnosis and 
treatment techniques, the reliance on medical devices such as catheters, stents, 
pacemakers, and implanted defibrillators to facilitate improved healthcare has increased 
drastically.1, 2 However, medical devices, especially percutaneous and transurethral 
catheters, are well known for their propensity to foster bacterial colonization and cause 
sepsis in hospital settings.3 Roughly 17 million hospital-acquired infections were reported 
in 2007 in the US alone, resulting in 100,000 deaths.1, 4 Treatment of such infections 
typically involves the use of antibiotics and broad-spectrum antimicrobials but even so, 
eventual device removal is often the only remedy. Left untreated, device infections lead 
to blood stream infection and ultimately sepsis. Unfortunately, the widespread use of 
antibiotics in the treatment of infections has resulted in the emergence of antibiotic-
resistant bacteria and fungi, further complicating treatment.  
Upon implantation of a medical device, proteins and small molecules present in 
the blood adsorb to the implant surface.5 Microbes present at the implantation site or 
from endogenous flora then migrate to the surface, attaching reversibly to the implant 
surface as a basal layer. Continued microbial colonization results in irreversible 
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surface attachment to the implant surface. Many species of bacteria and fungi, including 
P. aeruginosa and S. aureus, exude an exopolysaccharide matrix, forming a biofilm that 
increases the structural integrity of this microbial colony.6, 7 Following biofilm formation, 
microbes are between 30-2000 times less susceptible to antibiotics, making conventional 
antimicrobial treatments difficult.6 In the final stage of biofilm formation, microbes are 
released and may reattach in other locations, thus establishing new colonies and 
spreading the infection.6, 8 Due to the difficulty of treatment and the fastidious nature of 
biofilms, device removal is often necessary. 
The species of microbes implicated in medical device infections is diverse, further 
complicating prevention and treatment efforts. Both gram-positive and gram-negative 
bacteria adhere to medical devices, with staphylococci and enterococci being the most 
common.9 The species and strain of bacteria encountered in medical device infections 
depends upon the age of the recipient, the type of device, and preexisting disease. 
Bacteria most frequently encountered on IVCs include coagulase-negative staphylococci 
and S. aureus, which often originate from natural flora or contamination from healthcare 
workers, although gram-negative bacteria such as Enterobacter species are prevalent as 
well.10 Most often, single-species IVC infections will eventually result in colonization by 
multiple species. Pathogenic fungi has also been implicated in medical device infections. 
Candida albicans, the most widely encountered fungus, is found among the natural 
human microbial flora. This species is more difficult to treat than most bacteria due to the 
formation of elongated hyphae that enhance the structural rigidity of the biofilm.9 The 
stages of colonization and biofilm formation of C. albicans are illustrated in Figure 1.1.  
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Figure 1.1. Stages of C. albicans biofilm development on a substrate.  
 
 
 
 
 
 
Basal layer colonization
Fungal adhesion
Hyphal layer and exopolysaccharide (EPS) matrix 
formation
fungal cell
exopolysaccharide
Most susceptible  to treatment 
Least susceptible  to treatment 
(20‐3000x more resistant to 
antifungals)
<60 min
60 min – 24 h
> 24 h
Time since infection
4 
 
A method for preventing C. albicans adhesion and proliferation on medical device 
surfaces is described in Chapter 2 of this thesis. 
The probability of implant infections is dependent on the materials with which 
they are constructed. For example, although the reason is not well understood, silicone 
rubber IVC materials increase the risk of infection when compared to IVCs composed of 
polytetrafluoroethylene (PTFE), polyvinylchloride (PVC), and polyurethane.11, 12 Often, 
ideal polymers used to construct medical devices are limited by the mechanical properties 
required by the device. A more versatile strategy for developing antimicrobial implant 
materials is to modify the implant surface with an antimicrobial coating. A wide variety 
of passive and active-release coatings have been developed for reducing microbial 
adhesion and viability.  
1.1.1 Polymer coatings. The facile nature of polymer synthesis has enabled the 
development of coatings that resist the adhesion and proliferation of microbes. Polymers 
such as poly(ethylene glycol) (PEG),13 poly(vinyl pyrollidone) (PVP),14 and 
polyurethane15 have thus been evaluated as infection-resistant coatings for medical 
devices. For example, Kingshott et al. fabricated poly(ethylene glycol) coatings grafted to 
poly(ethyleneimine)-coated poly(ethylene terephthalate) (PET) or stainless steel (SS) 
substrates to improve antimicrobial efficacy.13 The authors reported that the adhesion of 
Pseudomonas aeruginosa to the PEG-coated PET was reduced by 2 to 4 orders of 
magnitude while no reduction in bacterial adhesion was observed to the PEG-coated SS 
surfaces. Thus, the authors concluded  that bacterial adhesion to PEG was highly 
dependent on the PEG attachment strategy. In another example, Tunney and Gorman 
evaluated the use of PVP-coated polyurethane for urinary catheters.14 The reduction of 
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bacterial adhesion was found to be dependent on the species evaluated, with significantly 
less Enterococcus faecalis adhered to PVP-coated and uncoated polyurethane, but no 
difference in E. coli adhesion.  
To enhance the antimicrobial efficacy of their surface, polymers have been 
modified with “polymer brushes.”16 As bacteria approach the interface or polymer brush, 
compression and osmotic repulsion create a barrier that discourages attachment. A variety 
of polymers have been utilized to synthesize polymer brush coatings. For example, 
Nejadnik et al. synthesized brushes on silicone rubber from polyethylene oxide and 
polypropylene oxide that resulted in a ~10 fold reduction in the adhesion of S. aureus and 
S. epidermidis.16 Unfortunately, neither a decrease in P. aeruginosa biofilm adhesion or 
viability was observed on the brush-coated surfaces in comparison to the silicone rubber. 
Polyacrylamide brushes attached to silicon wafers17 and silicone rubber18 have also 
shown some efficacy in reducing microbial adhesion. Cringus-Fundeanu and coworkers 
reported the synthesis of polyacrylamide brushes on to silicon wafers using atom transfer 
radical polymerization. 17 Utilizing a flow-cell adhesion assay, the authors found that S. 
salivarius, S. aureus, and C. albicans adhesion was reduced by 70-92% vs. untreated 
silicon. Although promising, grafting of the brushes to more clinically applicable 
substrates (e.g., silicone rubber and PVC) has not been demonstrated. 
Biomimicry represents a recent innovation in passive polymer coatings for 
infection control.19 Phosphorylcholine-based polymers that resemble phospholipid groups 
on cell membranes have been found to reduce bacterial adhesion. For example, Rose et 
al. reported that 2-(methacryloyloxyethyl phosphorylcholine)-based coatings resist 
bacterial adhesion, but only when pre-modified with heparin.20 Phosphobetaine-modified 
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polymer coatings have also been evaluated for use in reducing surface fouling. West and 
coworkers reported that the high wettability resulting from the phosphobetaine moiety 
prevents protein adsorption and reduces the attachment of S. aureus and S. epidermidis.21 
However, the synthesis of phosphobetaine-modified polymers is highly complex and 
cost-prohibitive. Another promising strategy for reducing implant infections is bacterial 
interference, where a polymer surface is intentionally colonized by benign bacteria, thus 
preventing the adhesion of pathogenic species. To successfully utilize this method, Lopez 
and coworkers functionalized a polydimethylsiloxane (PDMS) surface with amine-
terminated generation 5 (G5) poly(amidoamine) (PAMAM) dendrimers and then a 
carboxy-terminated mannose derivative.22 Benign E. coli expressing mannose binding 
proteins were then colonized on the surface and shown to reduce the adhesion of 
pathogenic Enterococcus by 2 orders of magnitude.  
 1.1.2 Antimicrobial-releasing coatings. The problem of microbial adhesion to 
implanted devices has often been addressed by designing surfaces/materials that slowly 
release antimicrobials from the interface. Large local concentrations of antimicrobials 
may be achieved by controlled delivery directly at the site where infection is likely. 
Furthermore, the type of antimicrobial may be tailored to the bacteria likely to be 
encountered in that environment. While the antibacterial efficacy of polymers doped with 
antibiotics has been reviewed extensively,6, 23 significant concern has arisen regarding the 
emergence of antibiotic-resistant bacteria as the rate of antibiotic delivery from a coating 
diminishes. Therefore, work has shifted to the design of coatings that release broad-
spectrum antimicrobials such as chlorhexidine, silver materials, and other 
macromolecular agents.  
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 The antimicrobial efficacy of silver (Ag) has been known for hundreds of years, 
and continues to be evaluated for a variety of applications including in medical device 
coatings.24, 25 Silver ions (Ag+) are believed to target amino acids, disrupting cellular 
activities and leading to microbial death.26 Kaali and coworkers utilized the antibacterial 
nature of zeolites containing Ag+ for medical device coatings by doping them into 
polyurethane.27 The authors exposed the zeolite-loaded polyurethanes to a variety of 
bacteria and fungi, and found that the antimicrobial effect increased with zeolite 
concentration. One downside to the use of antimicrobial silver compounds is low light 
and thermal stability. To address this issue, Gerasimchuk and coworkers synthesized a 
class of silver compounds known as silver (I) cyanoximates, and evaluated their 
antimicrobial efficacy as light and heat-insensitive dopants for medical device coatings.28 
By altering the electron withdrawing group on the cyanoximate, the authors found that 
the compound could be tailored for enhanced efficacy against a wide array of bacteria 
and fungus. Colloidal and nanoparticle forms of silver have also been used as 
antimicrobial agents due to their high storage capacity for and controlled release of Ag 
ions.29-32 Dair and coworkers evaluated the effect of the substrate material on the 
antimicrobial efficacy of silver nanoparticle-doped materials.33 By changing the surface 
charge, chemical reactivity, or affinity of the surface for the Ag ions, the rate of release 
and resulting local Ag+ concentration could be controlled. While the use of silver as an 
antimicrobial is common in a clinical setting, there is evidence that bacterial resistance to 
silver is emerging.34-36 In addition to silver, other metal ions that have been evaluated as 
antimicrobial dopants for medical device coatings include Cu(II), Zn(II), Al(III), and 
Fe(III).37 
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 Chlorhexidine, a skin and oral antiseptic that works by disrupting bacterial cell 
membranes, has also been evaluated for use in medical device coatings.38 Fong et al. 
incorporated chlorhexidine into polyurethane nanocomposites and found that it reduced 
the colonization of S. epidermidis by two orders of magnitude relative to controls.39 
Chlorhexidine has also been incorporated into medical cements, allowing for prolonged 
local release and reduced bacterial colonization.40 However, chlorhexidine has also been 
reported to have several adverse effects, including cases of anaphylactic shock and 
bacterial resistance.41  
 Antimicrobial peptides are an integral part of the innate immune defenses and 
provide potent, broad-spectrum antimicrobial activity by membrane disruption.42 A 
number of synthesized peptides  are currently being evaluated as potential antimicrobial 
therapeutics.43, 44  Strategies have recently been developed for tethering antimicrobial 
peptides to medical device surfaces.45 For example, Kazemzadeh-Narbat immobilized 
antimicrobial peptides to porous calcium phosphate coated on a titanium substrate.46 The 
authors reported that the resulting coating reduced the viability of gram-positive and 
gram-negative bacteria by 6 orders of magnitude after 30 min of incubation with minimal 
toxicity to human cells. Gao et al. conjugated antimicrobial peptides to hydrophilic 
polymer brushes via a covalent linkage between a maleimide group and thiol on the 
cysteine-modified peptide.47 By attaching multiple peptides on each polymer brush, 
loading of the antimicrobial peptides was maximized. The authors reported a ~6 order of 
magnitude reduction in the viability of P. aeruginosa exposed to the peptide-modified 
surfaces versus unmodified controls. While the use of antimicrobial peptides for 
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antimicrobial surfaces is promising, they are expensive to synthesize and handle, and thus 
are not yet well suited for clinical use. 
 1.1.3 Nitric oxide-releasing coatings. As an alternative approach to surface 
treatments and synthetic antimicrobials, we and others have developed coatings that 
release nitric oxide (NO), a broad-spectrum antimicrobial that has proven highly effective 
at reducing bacterial adhesion. In response to pathogens, phagocytes and other immune 
cells release an oxidative burst of nitric oxide.48 Both oxidative and nitrosative 
mechanisms subsequently result in antimicrobial activity, making NO highly effective 
against a wide variety of microbes.49, 50 The multi-mechanism activity also reduces the 
likelihood that a single mutation could result in microbial resistance. Chemical storage of 
NO is most often accomplished though the formation of a two NO moiety on a secondary 
amine (N-diazeniumdiolate) via exposure to high pressures of NO gas (Figure 1.2). 
Subsequent NO release is proton-triggered and may be enhanced by heating. Another 
method of storing NO chemically is the formation of a nitroso NO donor group on a thiol 
(S-nitrosothiol) via nitrosation of the sulfur group.51, 52 Release of the NO may be 
triggered by heat, light, or exposure to aqueous copper. Several materials have been 
devised to chemically store and release NO via N-diazeniumdiolate and S-nitrosothiol 
functionalities.53-62 Biomedical polymers already used for medical device construction 
such as polyesters56 and polyurethanes63 have been modified to release NO and proven 
effective at reducing colonization of P. aeruginosa.56 The Schoenfisch Group has focused 
on the synthesis of sol-gel-derived materials for NO storage and release.53, 61, 62, 64, 65 
Nablo et al. evaluated the antimicrobial efficacy of NO-releasing xerogels in a rat  
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Figure 1.2. Illustration of N-diazeniumdiolate formation on a secondary amine via 
exposure to high pressure NO and subsequent proton-triggered NO release. 
 
 
 
 
 
 
 
H2O
+ 2NO
NO
5 atm
11 
 
infection model by injecting a concentrated suspension of S. aureus directly into the 
implant site.64 The implants were removed after 8 d and the wound site interrogated. An 
82% decrease in the number of infected implants for the NO-releasing group versus non-
NO-releasing controls was observed. In a subsequent study, Hetrick et al. reported that 
aminosilane xerogels modified with NO reduced the adhesion and viability of P. 
aeruginosa in vivo versus non-NO-releasing controls by 65% and >96%, respectively. In 
Chapter 2 of this thesis, the efficacy of NO-releasing xerogels against the adhesion, 
viability, and biofilm formation of a highly pathogenic fungus is described as an 
extension of this research. 
1.1.4 Resistance to antimicrobials. The use of antimicrobial- and antibiotic-
releasing coatings has become popular, but with questionable efficacy due to the 
continued emergence of antibiotic-resistant strains.66, 67 Within many species of bacteria 
and fungi, the development of resistance to common antimicrobials hinders effective 
treatment and removal of biofilms.9, 68 Microbes have evolved to resist many outside 
stressors (i.e., antimicrobials) through a number of mechanisms including destruction or 
inactivation of the stressor, the modulation of normal biological processes and pathways 
(e.g., respiration), and active efflux.69 For example, only 2 years after the introduction of 
the antibiotic methicillin, a methicillin-resistant strain of S. aureus (MRSA) was 
identified.70 By adapting to produce the enzyme β-lactamase, S. aureus gained a 
resistance to a range of β-lactam antibiotics.71 Evidence of cross-resistance to multiple 
types of antibiotics has also become prevalent. For example, Vasquez et al. found that the 
use of nasally-administered mupirocin ointment to prevent MRSA infections resulted in 
the emergence of high-level mupirocin-resistant strains.72  Compounding the problem, 
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antibiotic resistance may be transferred genetically to other bacterial species. In one 
example, the increased use of β-lactam antibiotics resulted in the genetic transfer of β-
lactamase production to other organisms including Klebsiella pneumonia and Escherichia 
coli.71 Decreased susceptibility to broad-spectrum biocides such as quaternary 
ammonium compounds, chlorhexidine, and silver-based therapeutics is also becoming 
prevalent, along with initial evidence of cross-resistance between antibiotics and 
biocides.73-76 Contributing to this problem is the significant decrease in antimicrobial 
susceptibility observed for microbial biofilms.77, 78  
While researchers are developing novel therapeutics in an attempt to counteract 
this alarming trend, the pace of the development of effective chemotherapeutic agents has 
been comparatively slow.69, 79-81 Indeed, the need for improved passive antimicrobial 
strategies and/or antimicrobials that are biocidal via multiple mechanisms is significant, 
thus ensuring a lower likelihood of selecting for resistant microbes.82, 83 Nitric oxide 
represents one such antimicrobial that is biocidal via multiple mechanisms. However, no 
studies to date have examined the propensity of microbes to develop resistance to 
exogenous NO released from NO donors or macromolecular scaffolds (i.e., particles and 
polymers). In Chapter 4, both short- and long-term assays are used to evaluate bacteria 
developing such resistance.  
1.1.5 Superhydrophobic coatings. An effective example of non-fouling surfaces in 
nature is found on the leaves of the lotus plant. A combination of nano- and micro-
structured roughness and a low surface energy waxy coating result in a high water contact 
angle (>150°) that is referred to as superhydrophobic.84, 85 When a hydrophilic surface is 
tilted, water droplets slide across, lifting and redepositing any contaminants back on the 
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surface. Conversely, water acts like an elastic ball on a superhydrophobic surface and 
instead rolls across the substrate. Any contaminants are picked up by the spherical water 
droplet and carried away from the surface (Figure 1.3).85 Thus, superhydrophobic 
surfaces are often called self-cleaning surfaces. Synthetic superhydrophobic surfaces 
have been prepared by top-down methods (e.g., chemical etching, micromachining, and 
templating),84-88 bottom-up methods (e.g., chemical or layer-by-layer deposition, and 
colloidal assemblies),84, 85, 89-92 or a combination of both.  
 Although researchers have preciously evaluated the efficacy of superhydrophobic 
surfaces as antifouling coatings for marine hulls,88, 93 non-wetting coatings for optical 
surfaces,89, 92, 94 and anti-icing coatings for aircraft,93, 95, 96 only a few evaluations of 
superhydrophobic surfaces as antibacterial coatings for medical use have appeared in the 
literature.84, 97, 98 In an early report, Crick and coworkers synthesized superhydrophobic 
coatings on glass using chemical vapor deposition of a silicone elastomer to study 
whether such interfaces could reduce the adhesion of bacteria that cause infections. 97 The 
resulting surface was characterized by a water contact angle of 165°, reducing the 
adhesion of E. coli and S. aureus  by one order of magnitude. Fadeeva et al. utilized laser 
ablation, a top-down strategy, to fabricate superhydrophobic surfaces with static water 
contact angles of ~166°on titanium substrates.98 While the authors reported that S. aureus 
successfully colonized their surface, the adhesion of P. aeruginosa was completely 
inhibited. Yonghao and coworkers fabricated superhydrophobic coatings by depositing a 
eutectic liquid composed of tetraethoxysilane and choline chloride-urea on a substrate 
forming a porous sol-gel.99 
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Figure 1.3. Illustration of the “self-cleaning” mechanism of a superhydrophobic surface.
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The porous film was then coated with a low surface energy coating of fluoroalkoxysilane. 
The resulting coating reduced the attachment of E. coli while a glass slide control was 
completely colonized. While these strategies showed some success in vitro, none have 
been evaluated in a clinical setting. In addition, the aforementioned strategies for 
synthesizing superhydrophobic surfaces require complex synthesis strategies and 
equipment, and many are limited in terms of the substrate materials on which they can be 
employed. In Chapter 3, a simple strategy for synthesizing antimicrobial 
superhydrophobic surfaces that may be amenable to many substrates is described. 
 
1.2 Nitric oxide detection 
 Few diatomic molecules have received as much attention as nitric oxide (NO). 
Although well known as a potent environmental pollutant, it was not until 1987 that 
Furchgott, Ignarro, and Murad separately identified NO as the endothelium-derived 
relaxation factor (EDRF) by comparing the effect of NO and EDRF released from arterial 
and venous strips on adjacent vasculature.100-102 This discovery would ultimately lead to 
their shared Nobel prize in physiology in 1998 and spark interest in improved methods 
for detecting NO. In the years since this discovery, many scientists have continued to 
unravel the roles of NO in physiology. When produced endogenously from L-arginine by 
a family of enzymes called nitric oxide synthases (NOSs),103 NO has been found to be 
active in the cardiovascular,104 nervous,105 and immune106, 107 system, and in the wound-
healing process.108 Exogenously released NO has been shown to elicit diverse biological 
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responses such as reduced microbial viability109 and decreased platelet activation.61 In a 
clinical setting, NO has also garnered attention as a biomarker for sepsis.110-112 
Widespread interest in NO and its biological roles has generated demand for 
analytical techniques capable of its measurement and quantification. Such technology is 
not straightforward due to NO’s widely varying concentration. In the human body, the 
effect of NO is dependent on its concentration, ranging from sub-nanomolar to 
micromolar levels.113, 114 To complicate matters further, NO has a short half-life 
(typically <10 s) in biological milieu due to its reactivity with oxygen, thiols, free radicals 
and hemes.115 Effective NO detection schemes thus require a wide dynamic range, 
adequate sensitivity, and fast response time. Furthermore, the method must be highly 
selective toward NO over interfering species, which is often challenging due to the 
overwhelming complexity of biological systems.  
1.2.1 Indirect detection of NO. One of the earliest examples of the analytical 
detection of NO was reported by Griess in 1864.116 In the modern version of this method, 
now known as the Griess assay, NO is converted to nitrite (NO2-), a more stable 
byproduct of the reaction between NO and oxygen, and then reacted with sulfanilamide 
and N-(1-napthyl)ethylenediamine to form an azo dye. The concentration of the azo dye, 
typically measured using absorbance spectroscopy, directly relates to the concentration of 
nitrite, and thus NO in the original sample. Almost 150 years later, the Griess reaction 
remains the most commonly employed NO detection and quantification scheme. 
However, the Griess reaction remains poorly suited for measurements in biological 
systems where quick, real-time detection is necessary, where nitrite may fluctuate due to 
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other factors (i.e., dietary sources of nitrite), or when samples are opaque (e.g., blood). In 
addition, proteins present in biological matrices often cause further interfere.117 
1.2.2 Direct detection of NO. The majority of analytical approaches for measuring 
NO may be categorized as spectroscopic or electrochemical. Spectroscopic NO detection 
methods involve either indirect measurement of byproducts of reactions between NO and 
other chemical species (i.e., Griess reaction and chemiluminescence); or, direct 
measurement of adducts formed between NO and metal complexes (absorbance), 
fluorescent dyes (fluorescence), or spin traps (electron paramagnetic resonance 
spectroscopy).118 Some spectroscopic methods offer high sensitivity and selectivity for 
NO. For example, fluorescence detection is widely used for intracellular imaging of NO, 
enabling NO measurement at concentrations as low as 2 pM.119 However, most 
spectroscopic methods present obstacles for in vivo NO detection due to complex 
instrumentation that is difficult to miniaturize. Conversely, electrochemistry allows for 
direct NO analysis with attractive analytical performance (i.e., sensitivity, selectivity, 
response time, sensor size, and inexpensive fabrication and operation). 
1.2.3 Electrode materials. The materials used to construct an electrochemical NO 
sensor play a pivotal role in the sensitivity and quality of the ensuing analytical 
measurement. Materials often chosen as the working electrode include platinum (Pt) and 
its alloys,106, 120 carbon fiber,121 glassy carbon (GC),122 and gold (Au).123 By varying the 
composition and surface characteristics of the electrode material, the sensitivity, 
selectivity, signal stability, and required oxidation or reduction potential become tunable 
to varying extent. For example, Meyerhoff’s group found that platinum electrodes could 
be made more stable and sensitive to NO via platinization, a process where platinum 
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black particles are electrochemically formed on the electrode surface, increasing the 
roughness and effective surface area.124 By platinizing the platinum electrode of the NO 
sensor, 10-fold gains in both the NO detection limit and sensitivity were achieved. The 
authors surmised that the source of this performance enhancement was a concomitant 
increase in electron-transfer kinetics with a decrease in the potential required to drive the 
oxidation of NO.  
1.2.4 Electroactive biological interferences. Of the various examples of 
electrochemical NO sensors intended for biological applications, few have been tested 
against more than a handful of applicable biological interferences. The extent to which a 
particular interfering species influences an NO measurement depends on the type of 
sensor, the applied potential, the characteristics of the permselective membrane (i.e., 
surface charge, porosity, hydrophobicity, and thickness), and the intended biological 
location of analysis. For example, interference from gaseous oxygen is only a concern if 
NO is being measured via electroreduction, since the reduction potential for NO and 
oxygen are similarly negative. Predicting likely interfering species is further complicated 
by the dependence of NO and interfering species concentrations on a multitude of outside 
stimuli (e.g., disease, injury, age, nutrition, and prior medical history). The most 
commonly encountered interfering species in biological milieu and their typical 
biological concentration ranges are listed in Table 1.1.125-128 Nitrite is of particular 
concern due to its high concentration and similar size and oxidation potential to NO, 
making it difficult to discriminate between the two. Additionally, nitrite is a stable 
byproduct of the auto-oxidation of NO by endogenous oxygen and oxyhemoglobin, 
resulting in a direct dependence between the two species. Carbon monoxide (CO) is 
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equally problematic because of its similarities to NO in size, hydrophobicity, oxidation 
potential, and physiological roles.129 Recent studies have made it apparent that NO and 
CO regulate each other through various physiological processes.130 As a result, attempts 
to exclude CO using a NO selective membrane often fail. Providing selectivity to NO 
sensors over all of the aforementioned interfering species is clearly challenging and is 
discussed in more detail in the following sections. 
1.2.5 Sensor classification. A wide variety of sensor designs have been developed 
and adapted for use in the measurement of NO in solution. While the construction of 
these devices varies widely, sensors are typically composed of a surface capable of the 
electro-oxidation or -reduction of NO and a mechanism for discriminating against 
electroactive interferences. A permselective membrane is commonly employed for the 
latter. In general, sensor styles may be categorized as follows; 1) Shibuki-style, 2) solid 
permselective, and 3) solid catalytic (Figure 1.4).   
Shibuki-style NO sensors are modified versions of the initial oxygen (O2) sensor 
first reported by Leland Clark in 1956.131 This sensor comprises an electrolyte-filled 
micropipette into which both platinum working and silver reference wires are placed, and 
covered with a thin gas-permeable rubber membrane. Low molecular weight gases (e.g., 
NO and O2) easily diffuse through the membrane to the electrode surface while larger 
species are excluded. By applying a negative or positive potential at the platinum wire 
electrode, electroactive species are reduced or oxidized, respectively, at the electrode 
surface, resulting in current of magnitude proportional to the analyte concentration. 
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Table 1.1. Possible interfering species and their physiological concentrations during the 
electrochemical NO measurements. 
 
 
 
 
compound concentration range specimen ref.
nitrite <20 mMa blood (plasma) 129
ascorbic acid 34 – 114 mM blood (plasma) 126
uric acid 150 – 470 mM blood (serum) 126
acetaminophen 66 – 199 mMb blood (serum or 
plasma)
126
carbon monoxide 0.5 – 1.5 mMa mouse kidney 128
dopamine <2.0 nM blood (plasma) 126
norepinephrine 0.35 – 2.96 nM blood (plasma) 126
serotonin 0.28 – 1.14 mM whole blood 126
DOPACc 5.88 – 23.10 nM blood (plasma) 127
5-HIAAd 18.31 – 65.91 nM blood (serum) 126
aBasal concentration 
bTherapeutic concentration
cDOPAC, 3,4-dihydroxyphe-nylacetic acid
d5-HIAA, 5-hydroxyindole-3-acetic acid
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Shibuki reported the fabrication of the first NO-selective sensor in 1990, for which a 
positive electrode potential (i.e., electrooxidation) was used to oxidize and detect NO.132 
While this type of sensor measures NO with adequate selectivity over nitrite, the 
sensitivity of the sensor varied over time and between sensors from 2.5–106.3 pA/nM 
NO, leading to unstable measurements. In addition, the sensor was not readily amenable 
to miniaturization (>150 µm diameter) due to the complexity of construction and the 
requirement of an internal filling solution. 
Solid permselective NO electrodes have been developed to eliminate the need for 
an internal filling solution. Fabrication is accomplished by directly modifying a noble 
metal or carbon electrode with a typically hydrophobic membrane permeable to the 
analyte of interest but impermeable to other electroactive interferences.133 The simple 
design and construction of solid permselective electrodes allows them to be more easily 
miniaturized than Shibuki-style sensors. By layering multiple types of membranes on the 
electrode, the sensor selectivity may be tuned to discriminate over a wide variety of 
interferences including nitrite, dopamine, and acetaminophen, enabling unambiguous NO 
concentration determination in biological milieu. Nitric oxide is measured directly either 
by electrooxidation or electroreduction. 
Solid catalytic electrodes were developed to further reduce the effect of 
electroactive interferences on the NO-selective electrode. While similar in construction to 
solid permselective electrodes, the catalytic electrodes incorporate a mediator (e.g., 
metalloporphyrins and metal phthalocyanines) either directly on the electrode surface or 
within a permselective membrane.133 By including a mediator capable of catalyzing the 
oxidation or reduction of NO, the magnitude of the required electrochemical potential 
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(for NO measurement) is decreased, minimizing interference from other electroactive 
species. When combined with a permselective membrane, solid catalytic electrodes 
provide unparalleled selectivity. Similar to solid permselective electrodes, NO is 
measured directly either by catalytic electrooxidation or electroreduction. 
1.2.6 Modes of NO detection. While the majority of NO sensor-related 
publications involve the electrooxidation of NO (direct or catalytic), sensors that measure 
NO via its electroreduction have been reported.133-137 Depending on the electrode type 
and sample solution pH, NO is reduced at negative potentials ranging from -0.5 to -1.4 V 
(vs. Ag/AgCl).133 The reaction proceeds via a two electron reduction mechanism: 
 
2NO + 2e- → N2O22-  (4) 
 
The primary advantage of electroreduction is the avoidance of most interfering species 
that are commonly troublesome at positive potentials such as nitrite, ascorbic acid, and 
uric acid. However, electroreductive sensors are often plagued by diminished sensitivity, 
oxygen interference, and dependence on pH and electrode surface characteristics. With 
proper optimization, recent reports indicate some utility for specialized biological 
analysis.134-136 However, due the limited utility of NO detection via electroreduction, this 
introduction will not cover the topic in detail.  
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The electrochemical reaction of NO on metal surfaces at positive electrode 
potentials (typically 0.6 – 0.9 V vs. Ag/AgCl)138 proceeds via a three-electron oxidation 
mechanism: 
NO → NO+ + e–    (1) 
NO+ + OH- → HNO2     (2) 
HNO2 + H2O → NO3– + 2e– + 3H+  (3) 
During the third step of the reaction, nitrite is electrochemically oxidized to nitrate. As a 
result, endogenously produced nitrite presents a significant source of electrochemical 
interference.139 As nitrite is typically present in biological tissues at more than an order of 
magnitude higher concentration than NO, a successful NO electrode via electrooxidation 
must include a physical contingency for excluding it. Other common interfering species 
include acetaminophen, ascorbic acid, uric acid, dopamine, and CO. Careful attention 
thus must be given to understand the type and concentration of such interferences when 
making NO measurements with bare electrodes.  
 Since anionic (e.g., ascorbic acid and nitrite) and cationic (e.g., dopamine) species 
are significant sources of interference for electrooxidative measurements of NO in 
biological systems, exclusion by electrostatic repulsion is the most common method for 
imparting selectivity to NO sensors. Nafion, a polymeric cation exchanger (Figure 1.5), 
has been employed extensively to exclude nitrite via electrostatic repulsion from the 
sulfonate group present at neutral pH.123 In an early example of a permselective electrode  
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that selects against anionic species, Bedioui and coworkers coated gold fiber and 
microdisk electrodes with a Nafion film. In addition to providing good selectivity for NO, 
the electrodes exhibited a linear dynamic range for NO from 10–100 µM.123 While not 
exceedingly sensitive to NO, the authors noted that by decreasing the thickness of the 
Nafion membrane, sensitivity to NO was increased at the expense of selectivity over 
nitrite. Unfortunately, sensors coated with Nafion still respond to cationic and neutral 
species such as dopamine and acetaminophen, respectively.140  
 The ability to control the degree of hydrophobicity of an NO-selective membrane 
is important for maximizing sensitivity to NO and selectivity over interfering species. 
Utilizing multiple fluorinated alkylalkoxysilane precursors, Shin et al. demonstrated the 
ability to tune the hydrophobicity of NO-selective polymeric xerogel membranes, 
allowing for optimization of the sensor’s response to NO over electroactive 
interferences.141 The permeability and selectivity of the sensor to NO were maximized by 
utilizing a 20% (heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane (v/v, balance 
methyltrimethoxysilane) xerogel membrane applied to a 5 µm diameter Pt black/Pt-
coated conical tungsten microelectrode. The limit of detection and dynamic linear range 
of the NO sensor were 83 pM and 0.2 nM–4.0 µM, respectively. Furthermore, the sensor 
had little response to nitrite, ascorbic acid, uric acid, acetaminophen, dopamine, and 
ammonia.  
While the sensitivity and selectivity of direct electrooxidation NO sensors are 
dependent primarily on the permselective membrane, sensors that operate via catalytic 
electrooxidation utilize a redox mediator to further improve analytical performance. For 
example, metalloporphyrins may be immobilized on the electrode surface or incorporated 
27 
 
into a polymer coating to function as catalysts for the oxidation of NO. By increasing the 
electron transfer kinetics for NO oxidation, the sensitivity to NO is enhanced. The 
selectivity over interfering species is further improved by employing one or more 
permselective membranes.  
 Metalloporphyrins are the most common mediator chosen for fabrication of 
catalytic NO sensors. Nickel (Ni) is the most frequently employed central metal ion. In 
their seminal report, Malinski and Taha utilized a Ni-porphyrin electropolymerized on a 
carbon fiber subsequently modified with a Nafion film.121 In this configuration, the 
sensor had a detection limit of 10 nM and linear response up to 300 µM NO. When tested 
in solutions containing both NO and nitrite, the authors observed only a small increase in 
current and no change in peak potential indicating minimal interference from nitrite due 
to the lower oxidation potential employed. An important advantage of utilizing carbon 
fiber as an electrode is its small size and wide biological applicability. Indeed, the 
Malinski/Taha sensor was roughly 0.5 µm in diameter, and thus able to measure NO 
release from single endothelial and smooth muscle cells. In addition to the use of Ni 
porphyrins, porphyrins containing central metal ions such as iron (Fe) and manganese 
(Mn) have also been used to construct successful NO sensors.142-144 For example, Diab 
and Schuhmann coated platinum electrodes with Mn porphyrin-modified polypyrrole 
films, resulting in NO sensors with little interference from nitrite or ascorbic acid.144 
   1.2.7 Nitric oxide measurements in biological systems. Evaluation of the NO 
sensor literature reveals numerous examples of electrochemical NO sensors applied to 
biological systems. Previous reviews have described the biological applications of NO 
sensors.133, 138, 139, 145 A small selection of NO sensors applied to biological measurements 
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are detailed below as examples of the diversity of problems studied by these devices. 
Only sensors operating via electrooxidation (direct or catalytic) mode are described due 
to the interference from O2 encountered for electroreductive NO sensors. 
When making NO measurements in biological systems, it is important to consider 
the distance of the sensor from the NO source. Due to its rapid diffusion (3300 µm2 s-1) 
and reactivity in biological milieu, the concentration of NO will decay rapidly with 
increasing distance from the point of generation.114 Malinski’s group observed an 
exponential decrease in the NO concentration measured at a porphyrinic sensor with 
increasing distance from the source via stimulated NO release from a single endothelial 
cell. The researchers were able to measure, a concentration of roughly 950 nM  NO at the 
cell surface while NO was not measurable at distances >50 µm from the cell.146  
Size is another important parameter to consider when choosing a NO sensor 
design for a particular biological purpose. The diameter of most published sensors range 
from a few hundred nanometers to greater than two millimeters.138 Since the NO 
sensitivity of the sensor is directly proportional to the electroactive surface area, larger 
working electrodes typically offer greater NO sensitivity. However, the size requirement 
for a sensor depends greatly on the intended measurement location. For example, a 
micro- or ultramicroelectrode (<1 µm) is suitable for measuring NO in/near a single cell 
or a cluster of cells, while a larger sensor may be desirable for in vivo bulk NO 
measurements in blood. Ultramicroelectrode sensors offer the additional advantage of 
minimal perturbation of the surrounding environment upon use. Conversely, larger 
sensors are more robust and therefore less susceptible to failure over time. 
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Measurement of NO in blood is of particular interest due to its role in regulating 
vascular tone.114 Furthermore, the bioavailability of endothelium-derived NO is an 
important indicator of cardiovascular risk and has been found to be lower in patients with 
hypertension and diabetes mellitus.147 Evaluation of NO bioavailability has often been 
performed indirectly by observing the extent of vasodilation upon stimulation of NO 
release by bradykinin or acetylcholine (ACh).147 With the development of NO sensors, 
induced NO response is more accurately determined by direct measure of NO. 
Nevertheless, blood is a challenging environment for quantifying NO due to the presence 
of both dissolved oxygen and hemoglobin, scavengers of NO that lower circulating NO 
concentrations.  Sensors applied to in vivo NO analysis in blood must have excellent 
sensitivity to and selectivity for NO over its oxidation byproducts (e.g., nitrate and 
nitrite). In an early example of blood-based electrochemical NO measurements in human 
vasculature, a Nafion-coated metalloporphyrinic NO sensor was inserted into a hand vein 
to monitor stimulated NO release via infusions of bradykinin and acetylcholine.148 The 
resulting NO measurement revealed a dose-dependent relationship between the 
concentrations of the stimulating species and NO released. Injection of N-monomethyl- L-
arginine (L-NAME), a NOS inhibitor, attenuated the release of NO, indicating that the 
source of the observed signal was NO. Testing of selectivity during calibration indicated 
that the sensor was unresponsive to the chemical stimulants and inhibitor used during the 
course of the study. In addition, no signal was detected in response to nitrite or nitrate.  
 While a continued focus on improving the analytical performance of current 
electrochemical NO sensors is important, future research must address and improve the 
ability of NO sensors to resist biofouling for more reliable use in blood (i.e., protein 
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adsorption, platelet adhesion, and thrombus formation) and tissue (i.e., fibrous 
encapsulation and infection). Indeed, sensor biofouling often results in diminished 
analytical performance, poor reproducibility, and even failure. Previously published 
strategies for reducing biofouling on implantable sensors for other chemical species are 
reviewed elsewhere.149, 150 Briefly, current strategies include passive protection of the 
sensor through the use of sensor membranes that resist biofouling (e.g., polyurethanes, 
polyethylene glycol, Nafion, and phospholipids) and polymers that actively release 
antifouling agents.6 Ironically, a most promising approach for reducing biofouling of 
implantable sensors is based on NO release from the sensor interface.6, 151 Clearly, such a 
strategy would be problematic for NO sensors. 
 As researchers continue to unravel the complex biological roles of NO and 
develop therapies based on NO, the need for sensitive, selective, and accurate NO 
measurement devices will increase. Specifically, the use of clinical NO measurements as 
diagnostic and prognostic indicators for disease states necessitates inexpensive, small, 
and simple point-of-care devices. Electrochemical sensors, more than any other type of 
NO measurement technique, are well suited to fill this role. For practical purposes, 
electrochemical sensors remain most attractive for real-time in vivo NO quantification in 
biological systems. In addition to their ease of fabrication and miniaturization, the 
instrumentation required to perform ultrasensitive measurements is both affordable and 
potentially portable for field use. While few analytical sensors work well for all 
applications, the most successful designs are characterized by both desirable analytical 
performance criteria and ruggedness. The emerging development of new approaches 
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using nano-structured polymers and carbon nanotubes should further enable sensitive, 
selective, and accurate determinations of NO in challenging environments. 
 
1.3 Summary of dissertation research 
 The goals of my dissertation research include the synthesis and evaluation of 
antimicrobial sol-gel-derived coatings and the coupling of sensitive/selective NO 
measurement to microfluidic devices. Two separate strategies were utilized to explore the 
efficacy of antimicrobial coatings. In the first, the active release of NO from a sol-gel-
derived surface was evaluated for efficacy against the adhesion, viability, and biofilm 
formation of C. albicans. The ability of the superhydrophobic surface to resist bacterial 
adhesion was evaluated using a modified flow-cell and viability assay. Three separate 
methods were used to characterize C. albicans biofouling including a parallel-plate flow 
cell adhesion assay, a fluorescence nucleic acid probe viability assay, and electron 
microscopic evaluation of biofilm formation. A primary advantage of employing multiple 
assays was that they allowed for the evaluation of the efficacy of NO at all three stages of 
microbial colonization. In the second strategy, a passive superhydrophobic coating based 
on a sol-gel doped with fluorinated silica colloids was synthesized. A related study was 
devoted to understanding the likelihood that exposure to exogenous NO release would 
cause bacterial resistance to NO.  Both high-concentration, short term and low-
concentration, long-term exposure assays were utilized to cover the two most common 
conditions in which resistance is likely to occur. In a separate phase of research, a 
fluorinated sol-gel was utilized as a selective membrane to fabricate a microfluidic 
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electrochemical NO sensor. The primary advantages of using a microfluidic device as a 
platform for the NO sensor include low sample volumes and background noise.  
To summarize, the specific aims of my research included: 
1) determining the ability of NO-releasing xerogels to resist fungal adhesion 
under flowing conditions;  
2) study of the efficacy of NO-releasing xerogels against fungal biofilm 
formation;  
3) the synthesis and evaluation of sol-gel-derived superhydrophobic surfaces as 
antimicrobial coatings; 
4) evaluating the likelihood that exogenous NO release can foster bacterial 
resistance to NO; and, 
5) fabricating and characterizing a microfluidic electrochemical NO sensor. 
The intention of this introduction chapter was to introduce the fields of 
antimicrobial coatings, discuss the topic of bacterial resistance to antimicrobials, and 
overview methods for measuring NO. In Chapter 2, an evaluation of the antifungal 
efficacy of NO-releasing surfaces is reported. In Chapter 3, the synthesis and 
antimicrobial evaluation of sol-gel-derived superhydrophobic surfaces is presented. 
Chapter 4 presents an examination of the likelihood of NO resistance emergence upon 
exposure to exogenous NO release. Chapter 5 presents the fabrication and in vitro 
evaluation of a sol-gel-based microfluidic NO sensor. Finally, Chapter 6 is a summary of 
the work contained in this thesis and explains possibilities for future work that would 
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further develop the field of antimicrobial coatings and electrochemical NO detection, 
especially in the context of methods for the clinical detection of infection and sepsis. 
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Chapter 2  
Efficacy of Surface-Generated Nitric Oxide Against Candida albicans Adhesion and 
Biofilm Formation 
 
2.1 Introduction 
 Despite sterilization and the development of more hydrophilic coatings, invasive 
microbial infections remain a significant threat to the success of implanted medical 
devices, including indwelling catheters.1 Overall, >250,000 catheter-related blood stream 
infections are reported in the U.S. annually with a mortality rate up to 25% and 
significant financial burden.2 Candida albicans, a pathogenic fungus found naturally in 
the human gastrointestinal system, has been identified as the fourth most common 
pathogen isolated from catheters (behind coagulase-negative staphylococci, 
Staphylococcus aureus,  and enterococci).3 Furthermore, C. albicans is characterized by 
the second highest ratio of colonization to blood stream infection (coagulase-negative 
staphylococci and staphylococcus aureus), highlighting its virulence.4, 5 Although fungal 
infections are more common among immunocomprimised patients, the use of broad-
spectrum antibiotics in immunocompetent patients often eliminates natural competitive 
pressure from endogenous bacterial flora, increasing the risk of proliferation of other 
endogenous microbes and infection.6-9  
 Candida albicans infections typically originate at indwelling medical devices 
such as central venous catheters (CVCs). Characteristically, pathogenic colonization of 
medical devices occurs in four stages: adsorption of host proteins, adhesion of single cells 
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to the surface, formation of multiple basal layers, and growth of biofilm structures (e.g., 
hyphae, extracellular matrix).3 Fungal biofilms exhibit a greater resistance to antifungal 
agents (e.g., fluconazole and amphotericin B) than planktonic cells.3, 10, 11 Hawser and 
Douglas observed that the concentrations of five common antifungal agents used to 
reduce fungal metabolic activity by 50% were five to eight times higher for C. albicans in 
biofilms than planktonic cells.11 While systemic antifungals may be administered to 
combat fungal biofilm growth, strains resistant to common antifungals have emerged 
more recently.3, 10 
 Both passive and active strategies have been employed to mitigate fungal 
adhesion to medical implants.12 Passive strategies include surface modifications of 
polymer brushes,13 eugenol derivatives,14 and surface coatings of lauroyl glucose.15 In 
vivo, the utility of passive strategies remains limited, particularly in their ability to reduce 
the viability of attached microbes. Active release of antimicrobials16, 17 and antibiotics18 
have been shown to effectively reduce both the adhesion and viability of microbes on 
surfaces, but with increasing concern related to resistant strains,10, 19-24 necessitating the 
development of more effective antimicrobial agents. 
 Recent work has identified nitric oxide (NO), a highly reactive free radical, as an 
antimicrobial agent that is produced endogenously.25-28 Macrophages and other immune 
cells generate NO via inducible nitric oxide synthase (iNOS) in response to pathogens.29 
Restricting iNOS function and thereby limiting endogenous NO was shown by 
MacMicking et al. to result in greater infection rates.29, 30 While NO has been 
demonstrated as an effective antimicrobial, the potential clinical utility of NO-releasing 
drugs has been confounded by inadequate delivery. Indeed, sustaining effective NO 
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levels for a given application has proven most challenging.31 Our lab has employed sol-
gel chemistry to produce materials capable of sustained release of NO via 
diazeniumdiolate NO donors.27, 28, 32-36 Nitric oxide is stored as two molecule units on 
secondary amine moieties as a covalently-linked diazeniumdiolate NO donor.37 Such 
materials have proven beneficial in reducing bacterial adhesion in both in vitro and in 
vivo models,27, 28, 33, 35, 36, 38 and killing surface adhered bacteria.38 More recently, Hetrick 
et al. demonstrated that microbial biofilms can be effectively dispersed by NO released 
from silica particles.39 While some microbes may decrease their susceptibility to low 
concentrations of NO and its byproducts by increasing the production of antioxidant 
enzymes,29 examples or evidence of bacteria or fungus resistant to high concentrations of 
NO currently do not exist. Accordingly, interest in the therapeutic applications of NO as 
an antimicrobial continues to grow. 
 Although in vitro testing of the efficacy of NO generated by small molecule NO 
donors against planktonic Candida albicans has proven that NO is a potent antifungal,25, 
26 research regarding the effect of NO on the adhesion, viability, and biofilm formation of 
C. albicans remains incomplete.  Herein, the effectiveness of surface-generated NO 
against Candida albicans using model xerogel surfaces is evaluated with a parallel plate 
flow cell (fungal adhesion) assay, fluorescence nucleic acid staining, replicate plating on 
nutrient agar (viability of adherent fungal cells), and a biofilm growth assay. 
 
2.2 Materials and Methods 
 Isobutyltrimethoxysilane (BTMOS) was purchased from Aldrich (Milwaukee, 
WI). N-(6-aminohexyl)aminopropyl trimethoxysilane (AHAP3) was purchased from 
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Gelest (Morrisville, PA). Ethanol (absolute), hydrochloric acid, and tetrahydrofuran were 
purchased from Fisher Scientific (Pittsburgh, PA). Low molecular weight poly(vinyl 
chloride) (PVC) and silver sulfadiazine (AgSD) were purchased from Sigma-Aldrich 
(Tullytown, PA). Nitric oxide (99.5%) and argon (Ar) gases were purchased from 
National Welders Supply (Durham, NC). Class VI medical grade silicon rubber (0.60” 
thickness) was purchased from McMaster-Carr (Santa Fe Springs, CA). C. albicans 
(ATCC# 90028) was obtained from the American Type Culture Collection (Manassas, 
VA). Yeast peptone dextrose broth was purchased from Becton, Dickinson and Company 
(Sparks, MD). Nucleic acid stains SYTO©9 and propidium iodide (PI) were purchased 
from Invitrogen (Carlsbad, CA). Distilled water was purified to 18.2 MΩ·cm with a 
Millipore Milli-Q Gradient A-10 water purification system (Bedford, MA).  
2.2.1 Synthesis of AHAP3/BTMOS xerogel-coated films. Nitric oxide-releasing 
AHAP3/BTMOS xerogel-coated glass slides were synthesized as described previously.40 
Upon mixing ethanol (200 µL), BTMOS (180-120 µL), water (60 µL), and 0.5 M HCl 
(10 µL) for 1 h, AHAP3 (20-80 µL) was added to the solution and mixed for an 
additional hour resulting in a sol. The volume percentage of AHAP3 (balance BTMOS) 
was varied between 10 and 40%. Glass microscope slides were cut to 9 x 24 mm, 
sonicated in ethanol for 20 min, dried with N2, and UV-cleaned with a BioForce 
TipCleaner (Ames, IA) for 20 min. The sol (30 µL) was spread onto the clean glass slides, 
dried for 30 min in a dessicator, and transferred to a 70 ºC oven for 3 d. Xerogel-coated 
slides were then stored in a dessicator at room temperature until use. Xerogels formed in 
this manner are stable upon immersion in solution.36 
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 Nitric oxide-releasing 40% AHAP3 (v/v; balance BTMOS) xerogel-coated silicon 
rubber coupons for use in biofilm studies were synthesized as described previously.34 
Following the mixing of ethanol (1.2 mL), water (640 µL), and 0.5 M HCl  (110 µL), 
BTMOS (1.28 mL) was added dropwise, and the sol mixed for 18 h. AHAP3 (860 µL) 
was then added and the sol mixed for an additional 30 h. Class VI medical-grade silicon 
rubber (SiR) was cut into 8 × 6 × 2 mm3 coupons, cleaned via sonication in ethanol, 
sterilized in an autoclave at 120 ºC for 20 min, dried for 5 min in a 80 ºC oven, and then 
immobilized on sterile syringe needles. A xerogel surface was applied to the SiR coupons 
via dip-coating into the sol. The xerogel-coated SiR coupons were rotated at 1 rev/sec for 
3 d to facilitate even curing, then dried in a 50 ºC oven for 1 d. Xerogel-coated SiR 
squares were then stored in a dessicator at room temperature until use. 
2.2.2 Diazeniumdiolate modification of xerogels. Nitric oxide was loaded onto 
xerogels via exposure of the coated glass slides and SiR coupons to high pressures of NO. 
The film-coated slides and SiR coupons were placed in a Parr hydrogenation bomb, 
flushed with Ar at least six times to remove O2, and pressurized with 5 atm NO gas for 3 
d. Unreacted NO was then removed from the vessel by flushing with Ar. The NO donor-
modified xerogels were stored in a dessicator at -20 ºC until use to prevent 
diazeniumdiolate decomposition. 
2.2.3 Growth of standardized C. albicans suspension. Candida albicans was 
cultured in yeast peptone dextrose (YPD) broth at 37 ºC, pelleted by centrifugation, 
resuspended in 15% glycerol (v/v in PBS) and stored at -80 ºC. Cultures for fungal 
adhesion, viability, and biofilm studies were grown from a -80 ºC stock in YPD broth 
overnight. An aliquot of the overnight culture (1 mL) was inoculated into 100 mL sterile 
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YPD broth, incubated at 37 ºC with gentle agitation, and grown to 1 × 106 colony 
forming units (CFU) per mL as measured by optical density at 650 nm (OD650 ~0.044) 
and verified by serial 10-fold dilutions in PBS, plating on YPD agar, and enumeration of 
viable colonies. Cultures for viability and adhesion studies were pelleted by 
centrifugation (5000 rpm, 15 min) and resuspended in sterile PBS. Cultures for biofilm 
studies were diluted to 104 CFU/mL in YPD broth. 
2.2.4 Determination of fungicidal efficacy of AgSD. The efficacy of AgSD against 
C. albicans was determined at 24 h using a standard minimum bactericidal concentration 
(MBC24) assay. The MBC24 is defined as the minimum concentration of AgSD necessary 
to elicit a 3-log reduction in fungal viability after 24 h in growth conditions. Standardized 
fungal suspensions were tested against 5 different concentrations of AgSD. 
Concentrations of AgSD were chosen to bracket the MBC24 with a low and high 
concentration. 
  A 104 CFU/mL suspension of C. albicans in YPD broth was diluted to 2 × 104 
CFU/mL in YPD broth. A 2x concentration of AgSD in YPD broth was added to an equal 
volume of fungal suspension, resulting in a 104 CFU/mL fungal concentration and the 
desired final AgSD concentration. The number of viable fungi was determined via serial 
dilution and replicate plating on YPD agar at the beginning of the assay, and after 6 and 
24 h of incubation at 37 ºC on an orbital shaker.  
2.2.5 Flow cell-based fungal adhesion studies. A parallel plate flow cell assay 
was employed to examine the effect of surface NO flux on fungal adhesion to xerogel 
surfaces.34 Glass slides with control and NO-modified xerogels coated on one side were 
loaded into a custom-built polycarbonate flow cell device, forming chambers with 
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dimension 2.1 x 0.6 x 0.08 cm3. Two sets of three parallel flow chambers were placed in 
series so that three control xerogels were placed in front of three NO-releasing xerogels, 
allowing for 3 replicates to be measured in each experiment. A 106 CFU/mL C. albicans 
suspension in PBS (25ºC) was introduced over the xerogels at 0.2 mL/min using a three-
channel peristaltic pump. Fungal coverage to xerogel surfaces was measured by obtaining 
brightfield micrographs (10x magnification) in real-time at fixed timepoints (5, 20, 40, 60, 
90, 120, and 150 min) using a Zeiss Axiovert inverted microscope. Digital images were 
obtained using a Zeiss Axiocam digital camera (Chester, VA). Fungal adhesion was 
determined as a function of time using digital thresholding and quantified as percent 
surface coverage. 
2.2.6 Fluorescence-based qualitative viability studies. The viability of C. albicans 
adhered to control and NO-releasing xerogel surfaces was assessed qualitatively using a 
BacLight fluorescent probe nucleic acid stain assay (propidium iodide and SYTO©9). 
Fungal viability was measured both immediately following microbial adhesion to 
xerogel-coated glass slides and after incubation of adhered fungal cells at regular time 
intervals. By incubating xerogels with adhered fungus for extended periods, the effect of 
surface-based NO flux on fungal viability was assessed. Candida albicans fungi was 
grown to 106 CFU/mL in YPD broth as described above and resuspended in sterile PBS. 
Glass slides coated on one side with control and NO-releasing xerogels were incubated in 
the fungal suspension for 1 h at 37 ºC with gentle agitation to evenly adhere cells to the 
xerogel surface. The substrates were either transferred to a 5 mL solution of fluorescent 
probes (in PBS) or to 5 mL sterile PBS to maintain NO release. Xerogels incubated in 
fluorescent probes were removed after 30 min, rinsed in PBS, and dried gently in a N2 
54 
 
stream. Cell viability was assessed via fluorescence microscopy using a Zeiss Axiovert 
200 inverted microscope (Chester, VA) equipped with propidium iodide and cyto 9 filters 
(λ = 530 and 630 nm, respectively) from Chroma (Battleboro, VT). Digital images were 
obtained using a Zeiss Axiocam digital camera (Chester, VA). Brightfield and 
fluorescence micrographs of the xerogel sides of the glass slides were acquired at 10x 
magnification. Xerogels incubated in PBS for the time-based studies were fluorescently 
labeled and imaged as described above.  
2.2.7 Quantitative viability studies. The number of viable cells adhered to control 
and NO-releasing xerogels after long-term incubation in PBS was determined by 
removing cells and plating on nutrient agar. A standardized suspension of C. albicans 
(106 CFU/mL) in PBS (25ºC) was introduced over the NO-releasing xerogel-coated glass 
slides at 0.2 mL/min in the parallel plate flow cell. Flow of the fungal suspension was 
continued until surface coverage of the cells reached 20% as determined by optical 
microscopy and digital thresholding. Sterile PBS was then exchanged for the fungal 
suspension without passage of an air-liquid interface at a flow rate of 0.2 mL/min for 5 
min to remove non-adhered cells. For AgSD experiments, the fungal suspension was 
replaced with 160 µg/mL AgSD in sterile PBS. Flow was then stopped and the xerogels 
were left undisturbed for 15 h at ambient temperature, thus exposing fungal cells to a 
long-term NO flux. PBS was then removed from the flow cells at a flow rate of 0.2 
mL/min, and the slides subsequently removed and imaged at 10x magnification. Each 
slide was then transferred to 5 mL sterile PBS and sonicated for 15 min to remove 
adhered cells. Cell viability in the resulting PBS solutions was determined via 10-fold 
serial dilutions and plating on YPD nutrient agar, followed by enumeration of colony 
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forming units. Complete removal of cells was confirmed by evaluating the substrate 
surfaces using phase-contrast optical microscopy. 
2.2.8 Efficacy of surface-generated NO against fungal biofilms. Candida albicans 
was grown in YPD broth to 1 × 106 CFU/mL (OD650 ~0.044), and serially diluted to 1 × 
104 CFU/mL in YPD broth. Control and NO releasing 40% AHAP3-BTMOS SiR 
coupons immobilized on needles were sterilized under UV light for 20 min. An aliquot (5 
mL) of the 1 × 104 CFU/mL C. albicans suspension was added to sterile glass 
scintillation vials into which control and NO releasing SiR squares were immersed. Vials 
were incubated at 37 ºC with gentle agitation for 2 h to allow fungal adhesion. Substrates 
were immersed in sterile YPD broth at 37 ºC for 48 h to initiate biofilm growth, with a 
fresh supply of YPD broth introduced at 24 h.  For AgSD experiments, substrates were 
incubated in 160 µg/mL AgSD in YPD broth for 24 h, followed by fresh YPD broth. 
Biofilm-coated substrates were rinsed by immersion in sterile PBS, followed by sterile 
water to remove salts. Substrates were immediately affixed to a peltier device set at 11.5 
ºC in a FEI Quanta 200F scanning electron microscope. Electron micrographs (500 to 
1000x magnification) were taken in environmental mode (low vacuum, 5.15 torr) at 50% 
humidity using a gaseous secondary electron detector (GSED). 
 
2.3 Results and Discussion 
 
2.3.1 Nitric oxide release. Previous studies utilizing NO-releasing 
aminoalkoxysilane xerogels have demonstrated NO’s ability to reduce both bacterial 
adhesion and viability.28, 34-36 The optical transparency, stability, and NO release 
tenability (by varying aminosilane composition) of these materials makes them excellent 
model substrates for evaluating the effect of surface-generated NO on pathogenic fungus.  
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The AHAP3/BTMOS xerogel system was selected for this study due to the obtainable 
NO release at room and physiological temperatures (>48 h) and material stability.36, 40 
Furthemore, previous studies established that the surface properties (i.e., water contact 
angle) did not change after exposure to high pressure NO.40 The NO storage capacity was 
varied by synthesizing a range of compositions with an AHAP3 content from 10-40% 
(v/v, balance BTMOS). As expected, the flux, total amount, and NO release kinetics 
(measured as half-life) varied as a function of aminosilane composition and temperature 
(Table 2.1). For all compositions, NO release was characterized as a low but sustained 
flux at room temperature. At physiological temperatures (i.e., 37ºC), larger NO fluxes 
were measured, but at the sacrifice of release longevity. Indeed, the maximum NO flux 
from 10-40% (v/v) AHAP3 xerogels at room temperature was an order of magnitude 
lower than at 37 ºC. 
2.3.2 Flow cell based fungal adhesion studies. A flow-cell assay34 was utilized to 
assess fungal adhesion since the first stage of fungal colonization is the initial adhesion of 
cells to a substrate. An illustration of the parallel plate flow cell assay is shown in Figure 
2.1. As shown in Figure 2.2, lower fungal adhesion to the xerogel films was observed 
with increasing NO release. Absolute fungal adhesion results are provided in Table 2.2. 
Percent reduction versus controls, R, was calculated using the following equation:  
 
100×−=
con
NOcon
c
ccR          (3.1) 
where conc  and NOc  represent the percent bacterial surface coverage on the control and 
NO-releasing xerogel, respectively. After only 90 min, a 25% reduction in fungal 
adhesion was observed for NO-releasing 10% AHAP3 xerogels versus controls, 
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indicating that an NO flux as low as ~2 pmol cm-2 s-1 results in a significant reduction in 
fungal adhesion. Although an increase in the adhesion of C. albicans was observed at 
both control and NO-releasing xerogels at 150 min, the percent reduction in adhesion of 
all xerogel compositions versus controls remained unchanged. Furthermore, the 
differences in fungal adhesion between control xerogels were not statistically significant 
at any timepoint, regardless of aminosilane concentration. In contrast, the % fungal 
surface coverage observed for controls and all compositions of NO-releasing xerogels 
was statistically significant at both 120 and 150 min (p value < 0.05). As shown in Figure 
2.3 for 150 min, a clear trend of decreased fungal adhesion to NO-releasing xerogels with 
increasing AHAP3 content is apparent.  
To demonstrate that the NO release and not the surface chemistry of the xerogel 
film resulted in the reduced fungal adhesion, control and NO donor-modified 40% 
AHAP3/BTMOS xerogels were coated with a thin film of PVC prior to conducting the 
parallel-plate flow cell assay. As expected, a significant decrease in adhesion was 
observed for the NO-releasing xerogels versus controls (~28% reduction over controls), 
confirming that the NO alone leads to decreased fungal adhesion (Figure 2.4). The 
overall reduction in adhesion at the PVC-coated 40% AHAP3/BTMOS xerogels was 
lower than the non-PVC-coated xerogel due to the 20% reduction in NO release upon 
coating with PVC as previously reported.41 The influence of flow rate through the flow 
cell was also assessed (Figure 2.5). We expected a decrease in fungal adhesion at higher 
flow rates due to the increase in shear forces. However, a significant increase in fungal 
adhesion to control xerogels was observed at the greater flow rate (0.6 mL/min). While  
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Table 2.1. Average (from n=3) nitric oxide release at 25 and 37 ºC 10-40% AHAP3 
xerogels (balance BTMOS, v/v) in PBS (pH 7.4). *Total NO release over 15 h. 
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Table 2.2. C. albicans percent surface coverage to AHAP3 xerogels (balance BTMOS) 
under flowing conditions (0.2 mL/min) and calculated reduction in surface coverages to 
10-40% AHAP3 xerogels over controls (non-NO-releasing). 
90 min 150 min
% AHAP3 % surface coverage % reductionb % surface coverage % reductionb
Controla 45±5 N/A 65±4 N/A
10 33±5 27±5 50±5 23±3
20 32±2 29±4 46±3 29±3
30 28±4 38±7 43±2 34±3
40 23±4 49±10 31±7 52±12
a Controls are identical to the above xerogel compositions without NO release capabilities. No significant difference was observed
between controls of different compositions. Surface coverage values for controls are the average of all compositions.
b Over control.
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Figure 2.1. Illustration of parallel-plate flow cell adhesion assay. 
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Figure 2.2. C. albicans adhesion to xerogel-coated glass slides under flowing conditions 
(0.2 mL/min). Nitric oxide flux was varied by using 10 (●), 20 (▲), 30 (▼), and 40 (♦) 
AHAP3 xerogels (balance BTMOS, v/v). Control xerogels of all compositions were 
averaged (■) as surface coverage values at each timepoint were identical (within error). 
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Figure 2.3. Digitally thresholded phase contrast optical micrographs of C. albicans 
adhesion to control (A), and NO-releasing 20% (B), and 40% (C) AHAP3 xerogels 
(balance BTMOS, v/v) following 150 minutes of fungal exposure under flowing 
conditions (flow rate: 0.2 mL/min). 
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Figure 2.4. C. albicans adhesion to PVC-coated control (■) and NO-releasing (●) 40% 
AHAP3 xerogels (balance BTMOS, v/v) under flowing conditions (0.2 mL/min).  
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Figure 2.5. C. albicans adhesion to control (■ and ▲) and NO-releasing (● and ▼) 40% 
AHAP3 xerogels (balance BTMOS, v/v) under flowing conditions at a flow rate 0.2 
mL/min (■ and ●) and 0.6 mL/min (▲ and ▼).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
counterintuitive based on shear forces, we attribute these results to increased transport of 
C. albicans to the substrate. As expected, the NO-mediated reduction in adhesion to NO-
releasing xerogels versus controls was less pronounced at the larger flow rate (only ~8% 
reduction in surface coverage over controls at 0.6 mL/min) due to the more rapid 
clearance of NO from the xerogel surface. This observation provides further evidence of 
the primary role of NO in reducing fungal adhesion. 
2.3.3 Fungal viability studies. Critical to the success of indwelling catheters is the 
ability to both resist fungal adhesion and proliferation of adhered cells.4, 42, 43 To 
determine the effect of NO on the viability of adhered fungus in situ, a live/dead assay 
was conducted using a commercially available kit. While this assay has been used 
primarily to examine the viability of bacterial cells, Jin and coworkers previously 
validated its use for similar studies of C. albicans.44 We have previously demonstrated 
that the levels of NO released from xerogel films do not impact the probes (i.e., dyes) 
used in the assay.34 Candida albicans adhered (by soaking in a fungal suspension) to 
control and NO-releasing 40% AHAP3/BTMOS xerogels were incubated in PBS for up 
to 15 h. The fungi were then incubated in a solution containing the two fluorescent probes, 
SYTO9 and propidium iodide (PI), from a commercially available kit. Since only SYTO9, 
a green fluorescent dye, enters healthy cells, green fluorescence indicates viable cells. In 
contrast, red fluorescence suggests significantly compromised cells since PI, a red 
fluorescent dye, can only penetrate cells with damaged membranes. Example brightfield 
and fluorescence images of fungi adhered to control and NO-releasing xerogels at 0 and 
after 11 h incubation are provided in Figures 2.6 and 2.7, respectively.  
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Figure 2.6. Representative brightfield (A and D), syto 9 fluorescence (B and E), and 
propidium iodide fluorescence (C and F) optical micrographs (10x magnification) of C. 
albicans adhered to control 40% AHAP3 xerogels (balance BTMOS, v/v) taken 
immediately after preparation (A-C), and after 11 h incubation (D-F) in PBS (pH 7.4). 
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Fluorescence micrographs of fungus adhered to control xerogels taken both before 
(Figure 2.6B) and after 11 h of incubation in PBS (Figure 2.6E) exhibited only SYTO9 
fluorescence, indicating that cells adhered to controls are initially viable and remain so, 
even after 11 h in nutrient deficient conditions. In contrast, fungal cells exposed to an NO 
flux for 15 h had significant red fluorescence due to PI dye penetration (Figure 2.7D-F), 
even though such cells were viable at t = 0 h (Figure 2.7A-C). The emergence of 
fluorescence due to PI after 11 h of NO release indicated that the cell envelope was 
compromised. The PI fluorescence was not observed prior to 11 h incubation, suggesting 
that at earlier periods the level of total NO remained insufficient to cause cell damage 
(data not shown). In comparison to results published previously for P. aeruginosa, the 
time required for the appearance of PI was 37% greater.34 
 To gain a more thorough understanding about the relationship between NO flux 
and fungal viability, we evaluated the viability of adhered fungal cells using a range of 
NO-releasing xerogels (10, 20, 30 and 40% AHAP3-BTMOS). Viable cells were counted 
as colony forming units on nutrient agar. Candida albicans adhesion was first 
standardized at 20% coverage on the NO-releasing xerogels in a parallel plate flow cell 
(as described above) to allow direct comparison of fungal viability between each xerogel 
composition. After incubation for 15 h in PBS, adherent cells were removed from the 
xerogel surfaces in an ultrasonic bath, spread on nutrient agar and counted. Previous 
studies have shown this method of cell removal to be safe removing C. albicans from 
surfaces.45, 46 Removal of cells was confirmed after sonication by evaluating the surfaces 
using optical microscopy.   
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Figure 2.7. Representative brightfield (A and D), syto 9 fluorescence (B and E), and 
propidium iodide fluorescence (C and F) optical micrographs (10x magnification) of C. 
albicans adhered to NO-releasing 40% AHAP3 xerogels (balance BTMOS, v/v) taken 
immediately after preparation (A-C), and after 15 h incubation (D-F) in PBS (pH 7.4). 
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Of note, sonication of control xerogels resulted in incomplete removal of fungus cells, 
and therefore comparison to NO-releasing xerogels was not possible. Replicate plating 
experiments confirmed that cells were not killed during this period of sonication (data not 
shown). As expected, the number of viable cells removed from the xerogel surfaces was 
inversely proportional to the xerogel’s aminosilane content, and therefore the NO flux 
and total NO released from (Figure 2.8). Optical micrographs taken of each substrate 
after the 15 hr incubation in PBS but before removal of cells via sonication showed that 
the majority of cells are in their oval yeast form, rather than growing as hyphae (data not 
shown). While the total NO release from 10 and 40% AHAP3-BTMOS xerogels was 
0.049 and 2.077 µmol cm-2, respectively, the number of viable cells removed from 40% 
AHAP3 xerogels was ~42% less than that for 10% AHAP3 xerogels. The incomplete 
removal of fungus from controls further demonstrates the detrimental effect of NO on 
fungal adhesion. When compared to P. aeruginosa (96% decrease in viability between 
bacteria adhered to 10 and 40% AHAP3 xerogels),34 the observed reduction is attenuated.  
While the data suggests that NO-releasing materials may be effective at reducing 
fungal adhesion and proliferation, NO alone does not appear to be as potent against C. 
albicans as it is against other biofilm-forming bacteria. Decreased efficacy of NO against 
C. albicans may be attributed to cell size. Indeed, C. albicans are up to an order of 
magnitude larger in diameter than P. aeruginosa.47, 48 As a result, much of the yeast cell 
would be located further from the source of NO generation, minimizing exposure. 
Additionally, C. albicans are characterized by thick cellular envelopes (200–300 nm)49 
while P. aeruginosa, for example, is <50 nm.48, 49  
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Figure 2.8. Viable C. albicans removed from 10 – 40% AHAP3 xerogels (balance 
BTMOS, v,v) and 40% AHAP3 xerogels in the presence of a sub-fungicidal 
concentration of AgSD after 15 h of exposure of adhered fungus in PBS. Initial fungal 
surface coverage was identical at the start of the assay (20% coverage).   
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The thicker cell envelope may therefore afford C. albicans improved protection against 
NO and its reactive byproducts. Furthermore, a marked difference in the efficacy of 
broad spectrum antimicrobials such as chlorhexidine and silver sulfadiazine against C. 
albicans and P. aeruginosa has been reported by Schierholz and coworkers,50 suggesting 
that C. albicans may be less susceptible to broad spectrum antimicrobials in general.  
 To compensate for the decreased NO efficacy, the combination of NO and silver 
sulfadaziazine (AgSD) was investigated to further reduce colonization of implanted 
surfaces by C. albicans. McElhaney-Feser et al. previously reported that a combination of 
NO and azole-based antifungal agents resulted in synergistic killing (e.g., improved 
efficacy in combination than the sum of the efficacy of each individual agent).25 
Following a previous report,25 the efficacy of AgSD as an antifungal was determined by 
exposing C. albicans to a range of concentrations of AgSD in nutrient broth and 
measuring viability after 6 and 24 h (data not shown). Exposing C. albicans to a AgSD 
concentration of 800 µg/mL for 24 h resulted in complete killing (no viable cells). 
Although some growth inhibition was observed at 200 and 400 µg/mL AgSD, the cells 
remained completely viable (no inhibition) at a concentration of 100 µg/mL. Of note, no 
killing was observed at 6 h incubation at AgSD concentrations up to 1.6 mg/mL. To test 
the surface-localized anti-fungal efficacy of AgSD in combination with NO, fungal cells 
adhered to an NO-releasing 40% AHAP3-BTMOS xerogel were incubated in a PBS 
solution containing AgSD at a sub-fungicidal concentration of 160 µg/mL. As shown in 
Figure 2.8, the combination of NO and AgSD resulted in a ~95% reduction of viable cells 
compared to the NO release from 10% AHAP3-BTMOS xerogels alone.   
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2.3.4 Efficacy of surface-generated NO against fungal biofilms. Due to the ability 
of biofilms to protect microbes from therapeutics,3 we examined the effect of surface 
generated NO on the viability of preformed biofilms. Control and NO-releasing (40% 
AHAP3-BTMOS) xerogel-coated medical grade silicon rubber coupons were exposed to 
a fungal suspension for 2 h and then transferred to sterile nutrient broth for 2 d 
(transferring to fresh broth after 1 d) to facilitate biofilm formation. As expected, 
environmental scanning electron micrographs of each substrate revealed a substantial 
qualitative difference in the morphology of the biofilm between the control and NO-
releasing xerogels (Figure 2.9). Densely packed communities of fungus were found over 
large areas on control substrates (Figure 2.9A), while only small clusters of cells and 
hyphae were observed on the NO-releasing substrates (Figure 2.9C). These results 
suggest that surface-generated NO release alters biofilm growth. To test the effectiveness 
of the combination of NO and AgSD, biofilms were grown on control and NO-releasing 
xerogels in the presence of 160 g/mL AgSD. Controls with and without AgSD treatment 
were indistinguishable, confirming that the AgSD alone had little effect on biofilm 
growth at the chosen concentration (Figure 2.9B). When AgSD treatment was combined 
with NO release, only sporadic clusters of cells were present with no hyphal growth 
(Figure 2.8D). The absence of hyphae suggests that the combination of AgSD and NO 
release may arrested the growth of planktonic cells that managed to adhere.  
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Figure 2.9. Representative environmental scanning electron micrographs of C. albicans 
biofilms attached to control (A and B) and NO-releasing (C and D) 40% AHAP3-
BTMOS xerogels exposed to sterile YPD broth alone (A and C) and 160 µg/mL AgSD in 
nutrient broth (B and D). 
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2.4 Conclusions 
 The results described herein demonstrate that surface generated NO is an effective 
inhibitor of C. albicans adhesion at concentrations as low as ~2 pmol cm-2 s-1. The 
majority of adhered cells were killed, with viability dependent on the quantity of NO 
released. Biofilm formation was reduced when compared to formation on control and 
blank (bare SiR) substrates. Due to a reduced efficacy against C. albicans relative to 
pathogenic bacteria at similar NO concentrations, future studies will examine both the 
antifungal and cytotoxic properties of greater NO fluxes. Nevertheless, the synergy study 
suggests that the combination of surface-generated NO and sub-MBC concentrations of 
AgSD greatly increases killing over NO alone. Further studies will examine the 
antimicrobial efficacy effect of broad-spectrum leachable antimicrobials doped into NO-
releasing xerogels against C. albicans and other biofilm-forming fungus including C. 
parapsilosis and C. tropicalis. 
75 
 
2.5 References 
1. Hetrick, E. M.; Schoenfisch, M. H. "Reducing implant-related infections: active 
release strategies," Chemical Society Reviews 2006, 35, 780-789. 
2. O'Grady, N. P.; Alexander, M.; Dellinger, P.; Gerberding, J. L.; Heard, S. O.; 
Maki, D. G.; Masur, H.; McCormick, R. D.; Mermel, L. A.; Pearson, M. L.; Raad, 
II; Randolph, A.; Weinstein, R. A. "Guidelines for the prevention of intravascular 
catheter-related infections," Pediatrics 2002, 110. 
3. Douglas, L. J. "Candida biofilms and thier role in infection," Trends in 
Microbiology 2003, 11, 30-36. 
4. Crump, J. A.; Collignon, P. J. "Intravascular catheter-associated infections," Eur. 
J. Clin. Microbiol. Infect. Dis. 2000, 19, 1-8. 
5. Ramage, G.; Saville, S. P.; Thomas, D. P.; Lopez-Ribot, J. L. "Candida biofilms: 
an update," Eukaryot. Cell 2005, 4, 633-638. 
6. Cole, G. T.; Halawa, A. A.; Anaissie, E. J. "The role of the gastrointestinal tract in 
hematogenous candidiasis: From the laboratory to the bedside," Clinical 
Infectious Diseases 1996, 22, S73-S88. 
7. Pfaller, M. A.; Diekema, D. J. "Epidemiology of invasive candidiasis: a persistent 
public health problem," Clinical Microbiology Reviews 2007, 20, 133-+. 
8. Shin, J. H.; Kee, S. J.; Shin, M. G.; Kim, S. H.; Shin, D. H.; Lee, S. K.; Suh, S. P.; 
Ryang, D. W. "Biofilm production by isolates of Candida species recovered from 
nonneutropenic patients: Comparison of bloodstream isolates with isolates from 
other sources," Journal of Clinical Microbiology 2002, 40, 1244-1248. 
9. Wey, S. B.; Mori, M.; Pfaller, M. A.; Woolson, R. F.; Wenzel, R. P. "Risk factors 
for hospital-acquired candidemia: A matched case-control study," Arch Intern 
Med 1989, 149, 2349-2353. 
10. Chandra, J.; Mukherjee, P. K.; Leidich, S. D.; Faddoul, F. F.; Hoyer, L. L.; 
Douglas, L. J.; Ghannoum, M. A. "Antifungal resistance of candidal biofilms 
formed on denture acrylic in vitro," J Dent Res 2001, 80, 903-908. 
11. Hawser, S. P.; Douglas, L. J. "Resistance of Candida albicans biofilms to 
antifungal agents in vitro," Antimicrobial Agents and Chemotherapy 1995, 39, 
2128-2131. 
12. Hetrick, E. M.; Schoenfisch, M. H. "Reducing implant-related infections: active 
release strategies," Chem. Soc. Rev. 2006, 35, 780-789. 
76 
 
13. Nejadnik, M. R.; van der Mei, H. C.; Norde, W.; Busscher, H. J. "Bacterial 
adhesion and growth on a polymer brush-coating," Biomaterials 2008, 29, 4117-
4121. 
14. Rojo, L.; Barcenilla, J. M.; Vazquez, B.; Gonzalez, R.; Roman, J. S. "Intrinsically 
antibacterial materials based on polymeric derivatives of eugenol for biomedical 
applications," Biomacromolecules 2008, 9, 2530-2535. 
15. Dusane, D. H.; Rajput, J. K.; Kumar, A. R.; Nancharaiah, Y. V.; Venugopalan, V. 
P.; Zinjarde, S. S. "Disruption of fungal and bacterial biofilms by lauroyl 
glucose," Lett. Appl. Microbiol. 2008, 47, 374-379. 
16. Malcher, M.; Volodkin, D.; Heurtault, B.; Andre, P.; Schaaf, P.; Mohwald, H.; 
Voegel, J. C.; Sokolowski, A.; Ball, V.; Boulmedais, F.; Frisch, B. "Embedded 
silver ions-containing liposomes in polyelectrolyte multilayers: Cargos films for 
antibacterial agents," Langmuir 2008, 24, 10209-10215. 
17. Marini, M.; De Niederhausern, S.; Iseppi, R.; Bondi, M.; Sabia, C.; Toselli, M.; 
Pilati, F. "Antibacterial activity of plastics coated with silver-doped organic-
inorganic hybrid coatings prepared by sol-gel processes," Biomacromolecules 
2007, 8, 1246-1254. 
18. Rossi, S.; Azghani, A. O.; Omri, A. "Antimicrobial efficacy of a new antibiotic-
loaded poly(hydroxybutyric-co-hydroxyvaleric acid) controlled release system," 
Journal of Antimicrobial Chemotherapy 2004, 54, 1013-1018. 
19. Freitas, F. I. S.; Guedes-Stehling, E.; Siqueira-Junior, J. P. "Resistance to 
gentamicin and related aminoglycosides in Staphylococcus aureus isolated in 
Brazil," Lett. Appl. Microbiol. 1999, 29, 197-201. 
20. Chow, V. C. Y.; Hawkey, P. M.; Chan, E. W. C.; Chin, M. L.; Au, T. K.; Fung, D. 
K. C.; Chan, R. C. Y. "High-level gentamicin resistance mediated by a Tn4001-
like transposon in seven nonclonal hospital isolates of Streptococcus 
pasteurianus," Antimicrobial Agents and Chemotherapy 2007, 51, 2508-2513. 
21. De Lencastre, H.; Oliveira, D.; Tomasz, A. "Antibiotic resistant Staphylococcus 
aureus: a paradigm of adaptive power," Curr. Opin. Microbiol. 2007, 10, 428-435. 
22. Witte, W.; Cuny, C.; Klare, I.; Nuebel, U.; Strommenger, B.; Werner, G. 
"Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens," 
Int. J. Med. Microbiol. 2008, 298, 365-377. 
23. Percival, S. L.; Bowler, P. G.; Russell, D. "Bacterial resistance to silver in wound 
care," J. Hosp. Infect. 2005, 60, 1-7. 
24. Silver, S. "Bacterial silver resistance: molecular biology and uses and misuses of 
silver compounds," Fems Microbiol. Rev. 2003, 27, 341-353. 
77 
 
25. McElhaney-Feser, G. E.; Raulli, R. E.; Cihlar, R. L. "Synergy of nitric oxide and 
azoles against Candida species in vitro," Antimicrobial Agents and Chemotherapy 
1998, 42, 2342-2346. 
26. Weller, R.; Price, R. J.; Ormerod, A. D.; Benjamin, N.; Leifert, C. "Antimicrobial 
effect of acidified nitrite on dermatophyte fungi, Candida and bacterial skin 
pathogens," Journal of Applied Microbiology 2001, 90, 648-652. 
27. Nablo, B. J.; Prichard, H. L.; Butler, R. D.; Klitzman, B.; Schoenfisch, M. H. 
"Inhibition of implant-associated infections via nitric oxide," Biomaterials 2005, 
26, 6984-6990. 
28. Nablo, B. J.; Schoenfisch, M. H. "Antibacterial properties of nitric oxide-
releasing sol-gels," Journal of Biomedical Materials Research Part A 2003, 67A, 
1276-1283. 
29. MacMicking, J.; Xie, Q. W.; Nathan, C. "Nitric oxide and macrophage function," 
Annual Review of Immunology 1997, 15, 323-350. 
30. MacMicking, J. D.; Nathan, C.; Hom, G.; Chartrain, N.; Fletcher, D. S.; 
Trumbauer, M.; Stevens, K.; Xie, Q. W.; Sokol, K.; Hutchinson, N.; Chen, H.; 
Mudgett, J. S. "Altered responses to bacterial-infection and endotoxic-shock in 
mice lacking inducible nitric-oxide synthase," Cell 1995, 81, 641-650. 
31. Ghaffari, A.; Miller, C. C.; McMullin, B.; Ghahary, A. "Potential application of 
gaseous nitric oxide as a topical antimicrobial agent," Nitric Oxide 2006, 14, 21-
29. 
32. Charville, G. W.; Hetrick, E. M.; Geer, C. B.; Schoenfisch, M. H. "Reduced 
bacterial adhesion to fibrinogen-coated substrates via nitric oxide release," 
Biomaterials 2008, 29, 4039-4044. 
33. Dobmeier, K. P.; Schoenfisch, M. H. "Antibacterial properties of nitric oxide-
releasing sol-gel microarrays," Biomacromolecules 2004, 5, 2493-2495. 
34. Hetrick, E. M.; Schoenfisch, M. H. "Antibacterial nitric oxide-releasing xerogels: 
Cell viability and parallel plate flow cell adhesion studies," Biomaterials 2007, 28, 
1948-1956. 
35. Nablo, B. J.; Chen, T. Y.; Schoenfisch, M. H. "Sol-gel derived nitric-oxide 
releasing materials that reduce bacterial adhesion," Journal of the American 
Chemical Society 2001, 123, 9712-9713. 
36. Nablo, B. J.; Rothrock, A. R.; Schoenfisch, M. H. "Nitric oxide-releasing sol-gels 
as antibacterial coatings for orthopedic implants," Biomaterials 2005, 26, 917-924. 
78 
 
37. Hrabie, J. A.; Keefer, L. K. "Chemistry of the nitric oxide-releasing 
diazeniumdiolate ("nitrosohydroxylamine") functional group and its oxygen-
substituted derivatives," Chem. Rev. 2002, 102, 1135-1154. 
38. Hetrick, E. M.; Shin, J. H.; Stasko, N. A.; Johnson, C. B.; Wespe, D. A.; 
Holmuhamedov, E.; Schoenfisch, M. H. "Bactericidal efficacy of nitric oxide-
releasing silica nanoparticles," Acs Nano 2008, 2, 235-246. 
39. Hetrick, E. M.; Shin, J. H.; Paul, H. S.; Schoenfisch, M. H. "Anti-biofilm efficacy 
of nitric oxide-releasing silica nanoparticles," Biomaterials 2009, 30, 2782-2789. 
40. Marxer, S. M.; Rothrock, A. R.; Nablo, B. J.; Robbins, M. E.; Schoenfisch, M. H. 
"Preparation of nitric oxide (NO)-releasing sol-gels for biomaterial applications," 
Chemistry of Materials 2003, 15, 4193-4199. 
41. Nablo, B. J.; Schoenfisch, M. H. "Poly(vinyl chloride)-coated sol-gels for 
studying the effects of nitric oxide release on bacterial adhesion," 
Biomacromolecules 2004, 5, 2034-2041. 
42. Mermel, L. A. "Prevention of intravascular catheter-related infections," Ann 
Intern Med 2000, 132, 391-402. 
43. Miller, D. L.; O'Grady, N. P. "Guidelines for the prevention of intravascular 
catheter-related infections: Recommendations relevant to interventional 
radiology," J. Vasc. Interv. Radiol. 2003, 14, 133-136. 
44. Jin, Y.; Zhang, T.; Samaranayake, Y.; Fang, H.; Yip, H.; Samaranayake, L. "The 
use of new probes and stains for improved assessment of cell viability and 
extracellular polymeric substances in Candida albicans biofilms," 
Mycopathologia 2005, 159, 353-360. 
45. Lewis, R. E.; Kontoyiannis, D. P.; Darouiche, R. O.; Raad, II; Prince, R. A. 
"Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in 
vitro model of Candida catheter-related bloodstream infection," Antimicrobial 
Agents and Chemotherapy 2002, 46, 3499-3505. 
46. Sherertz, R. J.; Raad, II; Belani, A.; Koo, L. C.; Rand, K. H.; Pickett, D. L.; 
Straub, S. A.; Fauerbach, L. L. "3-Year experience with sonicated vascular 
catheter cultures in a clinical microbiology laboratory," Journal of Clinical 
Microbiology 1990, 28, 76-82. 
47. Sudbery, P.; Gow, N.; Berman, J. "The distinct morphogenic states of Candida 
albicans," Trends in Microbiology 2004, 12, 317-324. 
48. Matias, V. R. F.; Al-Amoudi, A.; Dubochet, J.; Beveridge, T. J. "Cryo-
transmission electron microscopy of frozen-hydrated sections of Escherichia coli 
and Pseudomonas aeruginosa," Journal of Bacteriology 2003, 185, 6112-6118. 
79 
 
49. Chaffin, W. L.; Lopez-Ribot, J. L.; Casanova, M.; Gozalbo, D.; Martinez, J. P. 
"Cell wall and secreted proteins of Candida albicans: Identification, function, and 
expression," Microbiology and Molecular Biology Reviews 1998, 62, 130-180. 
50. Schierholz, J. M.; Fleck, C.; Beuth, J.; Pulverer, G. "The antimicrobial efficacy of 
a new central venous catheter with long-term broad-spectrum activity," J. 
Antimicrob. Chemother. 2000, 46, 45-50. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  
Antibacterial Fluorinated Silica Colloid Superhydrophobic Surfaces 
3.1 Introduction 
The development of non-fouling coatings remains an important objective for the 
next generation of marine hulls, optical surfaces, and medical devices. Indeed, microbial 
fouling of biomedical devices (i.e., catheters, artificial joints) often results in blood 
stream infections (BSI) that have long plagued the healthcare industry. In 2002, 17 
million cases of hospital acquired infections were reported in the United States resulting 
in roughly 100,000 deaths and $45 billion in direct medical costs.1, 2 The increasing 
prevalence of these devices and the concomitant rise in associated infections have led to 
widespread dissemination of antibiotics, resulting in the emergence and rapid spread of 
drug-resistant microbes.3  
As such, the development of device coatings capable of resisting microbial 
colonization has become a major thrust of research with recent activity focusing on the 
active release of antibiotics4 or broad-spectrum antimicrobials such as silver ions or nitric 
oxide.5, 6 To date, concerns about toxicity,7 microbial resistance,3, 8 and finite release 
lifetime9 have limited the use and effectiveness of such coatings. Passive strategies 
including the physical or chemical modification of surfaces have been developed to resist 
bacterial adhesion in the absence of antimicrobial release, although such approaches have 
been pursued for decades with limited success.1 For example, polymers including
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polyurethane10 and poly(ethylene glycol) have been shown to reduce in vitro bacterial 
adhesion,11 but their in vivo effectiveness varies widely with surface chemistry, polymer 
composition and bacterial species.  
Ideal non-fouling coatings not only resist adhesion of fouling agents (i.e., 
microorganisms), but allow for easy removal of contamination that may occur. Examples 
of “self-cleaning” surfaces that exist in nature include lotus leaves and water strider legs. 
These surfaces are referred to as “superhydrophobic,” and exhibit static water contact 
angles >150º.12, 13 The preparation of synthetic superhydrophobic surfaces generally 
involves surface modification via nanoparticles, photolithography, mesoporous polymers 
or surface etching resulting in nanoscale surface roughness, sometimes in conjunction 
with additional chemical modifications to reduce surface energy.12, 14-16 The latter often 
require harsh synthetic conditions (e.g., etching and high temperature)17, 18 and complex 
fabrication techniques,19, 20 thus limiting the substrate type and geometry that may be 
coated.18, 19, 21 While previous reports have highlighted the utility of superhydrophobic 
surfaces for reducing fouling, few have evaluated the ability of such surfaces to resist the 
adhesion of medically-relevant bacteria.22-24 Of those evaluations published, assays were 
non-quantitative22 or did not evaluate the viability of attached bacteria.23, 24 Herein, we 
describe the synthesis of a superhydrophobic fluoroalkoxysilane coating that unlike 
previous reports makes use of mild reaction and curing conditions, and should enable 
modification of any substrates regardless of size or geometry. Using a quantitative 
bacterial adhesion/viability assay, we demonstrate the utility of this coating to reduce 
bacterial adhesion.  
 
82 
 
3.2 Materials and Methods 
3.2.1 Silica colloid synthesis. Silica colloids were synthesized by sonicating a 
mixture of (heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane (17FTMS) and 
tetraethylorthosilicate (TEOS) for 5 min. The amount of 17FTMS in the silane mixture 
was varied between 0 and 70 mol% (6.23 mmol total silane).  The silane mixture was 
then added dropwise to a stirred solution of 30 mL ethanol (absolute) and 12 mL 
ammonium hydroxide (28%, w:w) over 30 min to form silica colloids. After an additional 
20 min of mixing at room temperature, a white precipitate was collected via 
centrifugation at 4500 × g, washed twice with ethanol, and dried overnight under ambient 
conditions.  
3.2.2 Sol-gel film synthesis. Silica colloid-doped 17FTMS/methyltrimethoxysilane 
(MTMOS) films were prepared via dispersing 400 mg silica colloids in 9.4 mL cold 
ethanol via sonication, and then adding 17FTMS and MTMOS. The amount of 17FTMS 
in the silane mixture was varied between 0 and 40 mol% (1 mmol total silane). Following 
5 min of additional sonication, the mixture was added to a flask containing 2 mL H2O 
and 200 µL 0.1 M HCl and stirred for 1 h. The sol solution was spread-cast onto 
ozone/UV-treated glass slides (69.4 µL sol solution per cm2) and dried overnight, 
resulting in an opaque white film or xerogel. The control sols without colloids were 
spincast onto 9 × 24 mm glass substrates (200 μL at 3000 rpm for 10 s) as simple spread-
casting resulted in non-uniform coatings.  
3.2.3 Sol-gel film characterization. The wettability of the resulting surfaces was 
characterized via static water contact angle goniometry. Reported results are an average 
of 12 measurements.  Surface morphology was characterized via electron microscopy 
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after coating with 2.5 nm Au/Pd and imaging using a Hitachi S-4700 scanning electron 
microscope. Root-mean-square (RMS) roughness of the substrates was measured via 
atomic force microscopy, and were calculated from 20 µm2 images of three different 
substrates obtained in AC mode in air using an Asylum MFP-3D AFM and Olympus 
AC240TS silicon beam cantilevers (spring constant of 2 Nm-1). MFP-3D software was 
used for calculation of RMS values.  The stability of the coatings was assessed via daily 
contact angle measurements while soaking the substrates in water at 25 ºC for 15 d.  
3.2.4 Bacterial adhesion and viability assay. Bacterial adhesion to the substrates 
was characterized using a parallel-plate flow cell. S. aureus and P. aeruginosa were 
grown overnight from a frozen (-80 ºC) stock in tryptic soy broth (TSB) at 37 ºC, 
reinoculated in fresh TSB (37 ºC), and grown to 108 colony forming units (CFU)/mL as 
determined by optical density at 600 nm and verified by replicate plating on nutrient agar. 
The bacteria were pelleted via centrifugation (4500 × g, 15 min) and resuspended in an 
equivalent volume of PBS. The bacterial suspension was flowed over the xerogel 
substrates at 0.2 mL/min in a custom-machined polycarbonate parallel-plate flow cell 
(chamber dimensions = 2.1 × 0.6 × 0.08 cm3) for 90 min. The bacterial suspension was 
then exchanged with sterile PBS without passage of an air-water interface and flowed for 
another 20 min to rinse away any non-adherent bacteria. The substrates were removed, 
immersed in 5 mL sterile PBS, and subjected to ultrasonication for 15 min to remove 
adhered bacteria from the substrates. Bacterial suspensions were then serially diluted, 
plated on tryptic soy agar, and enumerated after incubation at 37 ºC for 24 h. 
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3.3 Results and Discussion 
3.3.1 Coating synthesis. Silica colloids were synthesized from 17FTMS (0 – 70 mol% 
total silane) and TEOS via base-catalyzed hydrolysis and condensation. The resulting 
silica colloids were composed of agglomerated silica particles with both micro-scale 
particle agglomerates (Figure 3.1A) and nano-scale individual particle definition (Figure 
3.1B). While agglomeration of irregularly-sized colloids would not be ideal for use as a 
therapeutic delivery vehicle, the varied structure was advantageous in for the use in a 
superhydrophobic coating. Xerogel coatings with and without added colloids were 
synthesized from 17FTMS (0 – 40 mol% total silane) and MTMOS via acid-catalyzed 
hydrolysis and condensation. The xerogel served as a low surface energy chemical 
modification to hold the silica colloids in place, as illustrated in Figure 3.2. Control 
surfaces consisted of 1) 17FTMS colloids without the additional 17FTMS xerogel 
coating (i.e., 100 mol% MTMOS); 2)  30 mol% 17FTMS/MTMOS xerogel coating 
without colloids; and, 3) a 100 mol% MTMOS xerogel coating without colloids.  
3.3.2 Surface Characterization. Contact angle goniometry (CAG) was used to 
measure static water contact angles of the control and silica colloid-doped xerogels. As 
shown in Figure 3.3, the optimal 17FTMS concentrations for both silica colloids alone 
and the xerogel blanks (without doped silica colloids) was 20-30 mol%. Increasing the 
17FTMS concentration above 30 mol% 17FTMS did not significantly increase the water 
contact angles, but negatively impacted the quality of the resulting films (data not 
shown). 
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Figure 3.1. Scanning electron microscopy images of 30 mol% 17FTMS-TEOS silica 
colloids at (A) 15000x, and (B) 36,600x magnification. 
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Figure 3.2. Illustration showing silica colloids cast within a thin fluorosilane film. 
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Thus, 30 mol% 17FTMS was used for all fluorinated colloid and xerogel film 
compositions. Static water contact angle images of the silica colloid-modified xerogels 
(superhydrophobic films) and controls, and blanks are shown in Table 3.1. The term 
“superhydrophobic” is typically given to any surface with a static water contact angle 
>150°, while the terms “hydrophobic” and “hydrophilic” are >90° and <90°, respectively 
(Figure 3.4). Doping the silica colloids into 17FTMS xerogels resulted in a 
superhydrophobic interface that was not achievable with silica colloids or 17FTMS 
xerogels alone. Scanning electron microscopy (SEM) images of the resulting silica 
colloid-containing fluorinated xerogel surfaces revealed a dense assembly of 
agglomerated particles consisting of both micro- and nano-scale features (Figure 3.5), 
which are prerequisite surface properties for obtaining superhydrophobicity.12 The 
17FTMS/MTMOS xerogel film was not apparent in the SEM images as it was spread as a 
thin coating on the high surface area created by the colloids. Both fluorinated and non-
fluorinated blank substrates (without colloids) were characterized with a slight surface 
roughness of 11.7 ± 0.3 and 1.5 ± 1.3 nm, respectively. As expected, the surface 
roughness of the 17FTMS colloid-doped substrates was much greater (898.5 ± 84.8 and 
573.8 ± 154 nm for fluorinated and non-fluorinated xerogels, respectively). The 
substantially greater surface roughness for the silica colloid-containing fluorinated 
substrates may be attributed to the assembly of the hydrophobic silica colloids within the 
hydrophobic 17FTMS. 
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< 90º > 90º > 150º
hydrophilic hydrophobic superhydrophobic  
Figure 3.3. Static water contact angles of (A) xerogel films, and (B) silica colloids as a 
function of the concentration (mol%) of 17FTMS (balance MTMOS and TEOS for films 
and particles, respectively). Data are represented as means ± SD (n = 15). 
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Figure 3.4. Static water contact angles of (A) xerogel films, and (B) silica colloids as a 
function of the concentration (mol%) of 17FTMS (balance MTMOS and TEOS for films 
and particles, respectively). Data are represented as means ± SD (n = 15). 
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Table 3.1. Static water contact angle measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 mol% 
MTMOS
30 mol% 17FTMS-
MTMOS
100 mol% 
MTMOS
30 mol% 17FTMS-
MTMOS
Surface
88.3 ± 5.5
Xerogel blanksSilica colloid-doped xerogel
104.7 ± 0.8167.7 ± 1.8151.0 ± 0.5Static water contact 
angle (degrees)
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Figure 3.5. Scanning electron microscopy images of 30 mol% 17FTMS (balance 
MTMOS) xerogel films doped with 30 mol% 17FTMS (balance TEOS) silica colloids at 
(A) 1500x, and (B) 15,000x magnification. 
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Indeed, comparison of scanning electron micrographs of both fluorinated and non-
fluorinated colloid doped substrates revealed flat islands of colloids on non-fluorinated 
surfaces but no such features on the fluorinated interface (Figure 3.6). The presence of 
the smoother colloid islands would be expected to reduce both the measured surface 
roughness and resulting superhydrophobic character of the films. The stability of the 
coatings was evaluated by soaking substrates in distilled water for 15 days while 
measuring the static water contact angle each day. Contact angles were maintained for all 
four substrates over this period (Figure 3.7), indicating that these xerogel-modified 
interfaces are sufficiently stable in aqueous solutions. Furthermore, the static water 
contact angle for the fluorinated superhydrophobic substrate (~167º) remained constant 
under the conditions of the bacteria experiment (25 ºC in phosphate buffered saline) over 
the course of the bacterial adhesion assay.  
2.3.3 Bacterial adhesion and viability assay. Bacterial infection of pin tracts 
represents the most common complication associated with external fixation of orthopedic 
biomaterials.25-27 We evaluated the adhesion of Gram-positive Staphylococcus aureus and 
Gram-negative Pseudomonas aeruginosa, strains common to pin tract infections, to 
control and superhydrophobic surfaces using a modified version of a conventional flow 
cell assay.  
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Figure 3.6. SEM images of A) a fluorinated xerogel (30 mol% 17FTMS-MTMOS) 
doped with silica colloids (30 mol% 17FTMS-TEOS) and B) a non-fluorinated xerogel 
(100 mol% MTMOS) doped with silica colloids (30 mol% 17FTMS-TEOS). White 
arrows indicate examples of smooth colloid islands. 
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Figure 3.7. Static water contact angles after immersion in distilled water at 25 ºC. A) 
Superhydrophobic 30 mol% 17FTMS (balance TEOS) colloid-doped 30 mol% 17FTMS 
(balance MTMOS) and B) colloid-doped 100 mol% MTMOS xerogels; C) blank (no 
colloids) 30 mol% 17FTMS (balance MTMOS) xerogels; and, D) MTMOS controls (100 
mol%). Data are represented as means ± SD (n = 12). 
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Many assays have been developed to evaluate bacterial adhesion and viability on 
surfaces. The most straightforward of these techniques is a static adhesion assay, where a 
coated substrate is incubated in a solution containing bacteria for a prescribed period. The 
extent of bacterial adhesion is then evaluated either qualitatively (i.e., bright field or 
electron microscopy) or quantitatively (i.e., ultrasonic removal of bacteria and plating on 
nutrient agar). Static adhesion assays are not ideal models for in vivo bacterial adhesion 
because the repeated passage of an air-water interface during substrate removal and 
rinsing often dislodges adhered bacteria before evaluation. Adhesion assays utilizing flow 
cells are a better model as exposure and rinsing steps may be performed without the 
passage of an air-water interface. In addition, flow may be controlled to mimic a 
particular biological environment. Although bacterial adhesion may be evaluated in real-
time using optical microscopy, quantification requires a transparent, relatively smooth 
substrate. Both static and flow techniques may be utilized to obtain semi-quantitative 
viability data by coupling the assay with fluorescent nucleic acid stains such as 
propidium iodide (enters only dead cells) and Syto 9 (enters both living and dead cells). 
To properly evaluate the superhydrophobic films in this study, a combination of a static 
and flow cell assay was utilized. Although the minimization of air-water interfaces 
afforded by the flow cell assay was necessary, the films were neither optically-
transparent nor microscopically smooth precluding the use of optical microscopy for 
quantification. Evaluation of bacterial adhesion was performed by removing the 
substrates from the flow cell prior to the rinse step, sonicating briefly in sterile PBS to 
remove adhered cells, and quantifying by plating on nutrient agar. An added advantage to 
this procedure is that unlike for optical microscopy, only viable bacteria were quantified.  
96 
 
As shown in Figure 3.8, the adhesion of S. aureus and P. aeruginosa to the silica 
colloid-doped fluorinated substrates was reduced by 99.0 and 98.2% (2.08 and 1.76 logs, 
respectively) versus the MTMOS blank. For silica colloid-coated substrates lacking the 
additional fluorosilane film modification, the reduction in S. aureus and P. aeruginosa 
adhesion versus MTMOS was an order of magnitude less at 87.4 (0.93 log) and 91.3% 
(1.10 log), respectively. Bacterial adhesion to fluorinated and non-fluorinated controls 
(without colloids) were identical within error as shown at A in Figure 3.8, indicating that 
the low surface energy of the fluorinated surface alone does not reduce bacterial 
adhesion. While these results suggest that the surface roughness of the silica colloid 
coatings alone may reduce bacterial adhesion, the low surface energy fluorosilane 
modification further improves the non-fouling nature of the surfaces as observed 
previously.28 Although the increase in static water contact angle upon fluorine 
modification was similar (~16º), only the colloid-containing substrates showed a 
measurable decrease in bacterial adhesion (1-log reduction for fluorinated versus non-
fluorinated). These results suggest that the greater surface roughness observed for the 
colloid-containing fluorinated surfaces plays a major role in the observed bacterial 
adhesion, compared to the 17FTMS coating alone.  
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Figure 3.8. Reduction in S. aureus and P. aeruginosa adhesion at (A) blank (no colloids) 
30 mol% 17FTMS (balance MTMOS) xerogels; (B) colloid-doped 100 mol% MTMOS 
xerogels; and, (C) superhydrophobic 30 mol% 17FTMS (balance TEOS) colloid-doped 
30 mol% 17FTMS (balance MTMOS) xerogels versus MTMOS controls (100 mol%). 
Data are represented as means ± SD (n = 9). 
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2.4 Conclusions  
The simple and flexible synthesis of silica colloid-based superhydrophobic 
surfaces has been reported and represents an important advance in developing non-
fouling surface coatings. The combination of micro- and nanostructured features from 
silica colloids and a low surface energy fluorinated silane xerogel resulted in surfaces that 
reduce the adhesion of highly pathogenic S. aureus and P. aeruginosa by ~2 orders of 
magnitude vs. controls, making these surfaces excellent candidates for further study as 
medical device coatings. By utilizing well-defined sol-gel chemistry for colloid and 
xerogel synthesis, the surface chemistry and physical properties of the resulting coatings 
may be tuned and optimized depending on the applications. Future studies will focus on 
the effect of colloid size, surface roughness, backbone silane structure and concentration, 
and protein preconditioning on bacterial adhesion. Furthermore, the bacterial adhesion of 
the superhydrophobic surfaces may be further reduced with additional silane precursor 
modifications that enable the active release of biocidal agents. For example, we have 
previously reported on silica nanoparticles and xerogels capable of releasing 
antimicrobial concentrations of nitric oxide.5, 29  
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Chapter 4  
Examination of Bacterial Resistance to Exogenous Nitric Oxide 
 
4.1 Introduction 
Nitric oxide (NO) is an endogenous diatomic free radical implicated in several 
physiological processes including vasodilation, immune response, neurotransmission, and 
wound healing.1 During infection, NO is released by macrophages and other immune 
cells at >1 µM concentrations where it serves as a broad spectrum biocidal agent.1-6 Nitric 
oxide induces both nitrosative and oxidative stress that results in numerous toxic effects 
on bacteria, including direct modification of membrane proteins, lipid peroxidation, and 
DNA cleavage.1, 6-8 As such, the exogenous application of NO as a therapy has been the 
subject of intense interest during the past decade.9-14  
Controlled NO storage and delivery using chemical NO donors has led to several 
pharmacological applications.15, 16 Example antimicrobial NO delivery vehicles include 
low molecular weight compounds (e.g., sodium nitroprusside, N-diazeniumdiolated 
proline, and S-nitroso-N-acetylpenicillamine),17-19 macromolecular vehicles,13, 14, 20-23 and 
polymeric coatings.9, 11, 24-32 We have previously reported the bactericidal activity of NO-
releasing silica nanoparticles and sol-gel-derived xerogel films against Pseudomonas 
aeruginosa at concentrations of minimal toxicity to mammalian cells.9, 13 
It is known that bacteria possess mechanisms for reducing the pharmacological 
effects of drugs such as antibiotics by decreasing their diffusion (i.e., efflux pumps), 
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overproduction or alterations of drug target sites, and enzymatic drug degradation.33-38 
Recent research also indicates that select bacteria are capable of up-regulating NO 
scavengers39-43 and/or altering respiration in response to endogenous NO.44 An example 
is NO detoxification by flavohemoglobin, a protein that is up-regulated in E. coli in 
response to macrophage-produced NO.45 Enzymes including reductases and superoxide 
dismutase have been implicated to serve similar functions.45, 46 With respect to cellular 
respiration, Husain et al. reported arrested respiration in Salmonella with concomitant 
accumulation of NADH, thereby increasing the ability of the bacteria to resist oxidative 
stress.47 
While the antimicrobial action of NO-releasing materials is established,9, 12, 13, 27, 
48-50 knowledge about the bacterial resistance to exogenous concentrations of NO remains 
scarce.39-44, 51 Miller et al. reported that S. aureus was not capable of developing 
resistance to exogenous gaseous NO; however, NO exposure was intermittent with 
discontinuous selective pressure against the NO-susceptible bacteria.52-55 Herein, we 
report a thorough bacterial resistance study using both spontaneous mutation and serial 
passage mutagenesis assays with continuous exposure to physiologically relevant 
concentrations of NO from NO-releasing silica nanoparticles. Representative gram 
positive and gram negative bacteria were selected to provide preliminary resistance 
information as a function of bacteria classification and structure. 
 
4.2 Materials and Methods 
4.2.1 Strains, media, and chemical reagents. 3-Mercaptopropyltrimethoxysilane 
(MPTMS) and tetraethoxysilane (TEOS) were purchased from Gelest (Tullytown, PA). 
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Bacteria were propagated at 37 °C in tryptic soy broth (TSB) and agar (TSA, Becton, 
Dickinson, Franklin Lakes, NJ). Sodium chloride, potassium chloride, sodium phosphate 
monobasic, methanol, ethanol, ammonium hydroxide, and hydrochloric acid were 
obtained from Fisher Scientific (Pittsburgh, PA). Sodium phosphate dibasic and sodium 
nitrite were obtained from Sigma Aldrich (St. Louis, MO). Escherichia coli O157:H7 
(35150), Pseudomonas aeruginosa (19143), methicillin-susceptible Staphylococcus 
aureus (MSSA) (29213), methicillin-resistant Staphylococcus aureus (MRSA) (33591), 
and Staphylococcus epidermidis (35983) were obtained from American Type Culture 
Collection (ATCC, Manassas, VA). Distilled water was purified to 18.2 MΩ·cm with a 
Millipore Milli-Q Gradient A-10 water purification system (Bedford, MA). 
4.2.2 Synthesis of mercaptosilane-based silica particles. Nitrosothiol particles (75 
mol% MPTMS/TEOS) were synthesized following a procedure reported previously.20 
Briefly, 3-mercaptopropyltrimethoxysilane (MPTMS, 424 μL) and tetraethoxysilane 
(TEOS, 169 μL) were mixed and added dropwise via a Kent Scientific Genie Plus syringe 
pump at a flow rate of 0.5 mL min-1 through an 18.5 gauge needle to a solution of ethanol 
(16.3 mL), water (1.4 mL), and ammonium hydroxide (11 mL). The reaction was stirred 
for 2 h at room temperature and the particles collected by centrifugation at 3645g (10 
min), washed twice with 40 mL EtOH, recollected, and dried overnight at ambient 
conditions. 
4.2.3 Nitrosation of mercaptosilane-based silica particles. Thiols within the 
particles were nitrosated upon reaction with nitrous acid as follows. Particles (~200 mg) 
were first added to 4 mL methanol (MeOH). While stirring, 2 mL of hydrochloric acid (5 
M) was added to the suspension. A 2 mL aqueous solution containing sodium nitrite (2x 
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molar excess to thiol) and DTPA (500 µM) was then added to the particle suspension, 
and the mixture was stirred for 2 h in the dark on ice.  Particles were collected by 
centrifugation at 3645g (5 min), washed with 40 mL chilled 500 µM DTPA(aq), 
recollected, washed with 40 mL chilled MeOH, recollected, and vacuum dried in the dark 
for 30 min. Particles were stored at –20 °C in vacuo until used. 
4.2.4 Nitric oxide release characterization. Real-time NO release from 75 mol% 
MPTMS/TEOS particles was measured at 1 s intervals using a Sievers 
Chemiluminescence Nitric Oxide Analyzer (Boulder, CO). Particles were added to 25 
mL deoxygenated TSB (37 °C) containing 50 µL antifoaming agent B (Sigma-Aldrich) to 
prevent frothing. The solution was sparged with nitrogen (80 mL/min) with additional 
nitrogen was supplied to the reaction flask to match the collection rate of the NOA (200 
mL min-1). The apparatus was covered with aluminum foil to prevent light-initiated 
nitrosothiol decomposition. 
4.2.5 Minimum inhibitory concentration assay. Bacterial cultures were grown 
from an overnight stock in TSB to 108 colony forming units (cfu) mL-1 and diluted to 2 × 
106 cfu ml-1. Bacteria were added to serial dilutions of nitrosothiol particles in a 96-well 
plate resulting in a final concentration of 106 cfu mL-1 bacteria. After incubating by 
shaking for 24 h at 37 °C, MIC values were determined as the lowest particle 
concentration not supporting bacterial growth (i.e., not turbid).   
4.2.6 Spontaneous resistance assay. Bacterial cultures were grown from an 
overnight stock in TSB to ~1010 cfu mL-1. A 1-mL aliquot of the 109 cfu mL-1 culture was 
added to NO-releasing particles at 2–8× the MIC. Following a 24 h incubation at 37 °C in 
the dark with agitation, 1 mL of each concentration was plated on TSA (200 µL on 5 
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separate plates) and incubated overnight at 37 °C. Surviving colonies were propagated 
overnight at 37 °C in TSB, reinoculated and grown to 108 cfu mL-1. The MICs for 
propagated strains were determined using the above procedure and compared to the 
parent strain. Surviving colonies on TSA that could not be propagated in TSB were 
passaged on TSA for three days and then grown in TSB overnight at 37 °C. If overnight 
growth in TSA was successful, the MIC was then evaluated and compared to the parent 
strain. Otherwise, formation and settling of a bacterial precipitate did not allow an MIC 
assay to be performed. 
4.2.7 Serial passage assay. Bacterial cultures were grown from an overnight stock 
in TSB to 108 cfu mL-1 and diluted to 2 × 106 cfu mL-1. The bacterial suspensions were 
then added to serial dilutions of nitrosothiol particles in a 96-well plate resulting in wells 
containing 106 cfu mL-1 bacteria and nitrosothiol particle concentrations of 2, 1, 0.5, 0.25, 
and 0.125× the MIC (n=3). After incubating by shaking for 24 h at 37 °C, MIC values 
were recorded, and an aliquot from the well containing the highest particle concentration 
that supported bacterial growth was diluted to 2 × 106 cfu mL-1. The MIC assay was 
performed using this bacterial suspension. The entire process was repeated for 20 
exposure cycles. 
 
4.3 Results and Discussion 
The bacterial species used in these studies were selected because they are 
frequently found in a clinical environment. While gaseous NO has proven useful for 
pulmonary treatment, it is generally not a good candidate for an antimicrobial therapeutic. 
The short half-life (<10 s) of NO in physiological milieu prevents its delivery to common 
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infection sites such as an indwelling medical device (i.e., catheter) or deep wound. As 
such, nanoparticles chemically modified to store and release NO have been studied 
widely as candidate antimicrobials.12-14 We have previously described particles that 
release NO over extended periods (from minutes to days), allowing more targeted NO 
delivery, thus ensuring more lethal concentrations of NO. Indeed, Hetrick and coworkers 
reported excellent efficacy of NO-releasing particles against both planktonic and biofilm-
based bacteria.12, 13 To date, the only studies that have examined bacterial resistance to 
exogenous NO have used NO gas from cylinders.52-55 Martinez and Baquero 
demonstrated that the development of resistant bacteria depends on antibiotic exposure 
parameters (i.e., concentration and kinetics).56 Thus, we utilized chemically-stored NO 
release for these studies to more fully evaluate resistance potential. In particular, 
nitrosothiol-based NO-releasing particles were selected because their extended NO 
release capabilities (>24 h) facilitate continuous selective pressure for resistant mutants 
whereas low molecular weight N-diazeniumdiolate NO donors tend to release their NO 
payload more quickly, especially in aqueous media.13, 20  
The NO release profile of 75 mol% MPTMS-TEOS particles (635 ± 63 nm 
diameter) in TSB at 37 °C is shown in Figure 4.1. To mimic the conditions used during 
the bacteria assays, NO release measurements were conducted in the absence of light 
such that NO production was limited to thermal decomposition and not photolytic 
cleavage. Upon addition to the assay media (2 mg mL-1 final particle concentration) 
(TSB,37 °C), a bolus of NO was released at ~740 ppb mg-1 s-1. This level of NO 
decreased with time, ultimately dropping to ~11 ppb mg-1 s-1 after 24 h. Over the course 
of the assay, a total of 0.90 µmol mg-1 was released per mg of particles. Both the  
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Figure 4.1. Representative NO release from 75 mol% MPTMS/TEOS particles in TSB at 
37 °C. [Inset: Enlarged view of NO release during 12–24 h. 
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maximum instantaneous and the total NO released from the particles in TSB were 
slightly lower than reported previously in PBS (1205 ppb mg-1 s-1 and 1.17 µmol mg-1, 
respectively), which is likely due to reactions between NO and proteins present in TSB.20 
4.3.1 Miniminum inhibitory concentration determinations. Minimum inhibitory 
concentrations were used to rapidly determine the efficacy of the NO release and monitor 
for the emergence of resistance.56-59 As shown in Table 4.1, the MICs were used for both 
the spontaneous and serial passage mutagenesis assays. The MIC of 75 mol% 
MPTMS/TEOS particles for each bacterial species was determined under growth 
conditions (TSB, 37 °C) over 24 h. The measured MICs ranged from 3.13 to 6.25 mg 
mL-1 across all bacterial species (Table 4.1).Of note, the MICs for both methicillin-
susceptible and -resistant S. aureus were half that of S. epidermidis and the two Gram 
negative species, E. coli and P. aeruginosa.  
4.3.2 Spontaneous mutagenesis assay. Even after exposure to bactericidal doses 
of an antimicrobial, some microbes may survive depending on the antimicrobial 
concentration, environmental conditions, and microbial species.56 In the case of 
antibiotics, some of the surviving microbes are the result of a spontaneous mutation that 
confers greater resistance to future treatment.56 Thus, the rate of spontaneous mutations 
occurring at inhibitory NO concentrations was evaluated for each bacterial species to 
address the possibility of NO-resistance. Nitric oxide-releasing particle concentrations 
ranging from 2 to 8 times the MIC were utilized to provide adequate selective pressure 
against NO-susceptible bacteria. Surviving colonies were isolated and propagated in 
TSB, and the MIC assays were repeated to observe if the microbes were more or less 
susceptible to NO treatment. Exposure of E. coli to NO-releasing particles at 2 times the 
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MIC resulted in 19 surviving colonies in 1 mL. Each colony was reinoculated in TSB, 
and all resulted in a cloudy suspension after overnight incubation. An MIC assay was 
performed individually on each colony and the susceptibility of all 19 colonies was 
unchanged from the parent strain (6.25 mg mL-1). An illustrative overview of the 
spontaneous mutation assay is shown in Figure 4.2. Nanoparticle exposure to MRSA at 7 
times the MIC resulted in one surviving colony in 1 mL. Although the MIC of this 
survivor was increased by 2 times to 6.25 mg mL-1, this increase is considered to be 
within the experimental variation and is thus not significant. After exposure of P. 
aeruginosa to 2 times the MIC, 7 surviving colonies were isolated and propagated 
successfully in TSB. The MIC of all P. aeruginosa survivors was increased two fold to 
12.5 mg mL-1, but again this increase is within the experimental variation and not 
significant. 
Some colonies that were able to survive NO treatment were not able to grow 
successfully in TSB. These colonies were instead propagated three times on TSA to 
assess if the mutation that limited growth in broth was stable. After exposure of S. 
epidermidis to 4 times the MIC, two of the three surviving colonies could not be 
propagated further in TSB, even after three successful passages on TSA. Regrowth of the 
bacterial precipitate was possible on TSA. However, the lack of growth to turbidity in 
TSB prevented the determination of the MIC.  The spontaneous mutation that resulted in 
this NO tolerance seemed to have prevented regrowth in nutrient broth. Others have 
observed similar behavior where mutations conferring resistance to a therapeutic also 
result in a fitness cost to the bacteria, sometimes preventing further propagation.60, 61 A 
third colony of S. epidermidis was successfully regrown in TSB, but viability was not  
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Figure 4.2. Illustrative overview of the spontaneous mutagenesis assay. 
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evident following NO exposure even at 1/8 of the MIC. To assess the fitness of this 
colony, it was propagated three times in succession on TSA and then inoculated in TSB. 
The solution again grew to a cloudy suspension overnight. An MIC assay was 
successfully completed and found to be identical to the parent strain (~6.25 mg mL-1). 
These results indicate that for one mutant, the growth defect preventing propagation in 
TSB in the absence of NO was resolved, possibly due to a second mutation that also 
abolished the observed increase in NO resistance.  
Methicillin-susceptible S. aureus exposed to 8 times the MIC resulted in 12 
surviving colonies on TSA. Reinoculation of each colony in TSB produced a precipitate 
similar to that of the S. epidermidis colonies described above. Similarly, the colony failed 
to successfully grow to a cloudy suspension in TSB after regrowth on TSA three times in 
succession. Therefore, no MIC assay was performed. However, propagation of the 
bacteria aggregate on TSA was successful. A comparison of all parameters (initial and 
final MIC, survivors, and colonies propagated in TSB) is shown in Table 4.1. 
4.3.3 Serial passage assay. Repeated exposure to sub-therapeutic concentrations 
of antibiotics often hastens the development of antibiotic-resistant bacteria.62, 63 Genetic 
mutations may result, leading to an increased resistance to the antibiotic that the microbes 
were exposed to at subcidal or subinhibitory doses. Repeated or prolonged exposure to 
sub-therapeutic antibiotic concentrations would further enrich the resistant strain. To 
investigate possible resistance, the susceptibility to NO treatment following exposure to 
sub-inhibitory NO doses was examined using the NO-releasing nitrosothiol-modified 
particles. Bacterial cultures were treated with a range of concentrations both above and 
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Table 4.1. Minimum inhibitory concentrations of 75 mol% MPTMS/TEOS particles in 
TSB at 37 °C for 24 h and spontaneous mutation parameters before and after exposure to 
inhibitory concentrations of NO. 
 
 
 
 
 
 
 
 
 
 
 
species ATCC #a MIC24h(mg mL-1)
Exposure concentra tion
(mg mL-1)b
Survivors after >MIC 
NO exposure
Colonies propagated 
in TSB
Final MIC24h
(mg mL-1)
S. aureus 29213 3.13 25.0 12 0 N/Ac
MRSA 33591 3.13 21.9 1 1 6.25
S. epidermidis 35983 6.25 25.0 3 1 6.25
E. coli (0157:H7) 35150 6.25 12.5 19 19 6.25
P. aeruginosa 19143 6.25 12.0 3 6 12.5
aATCC, American Type Culture Collection.
bStartingbacterial concentrations were ~1010 cfu mL-1.
cRegrowth in broth did not result in turbidity, thus an MIC could not be performed.
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below the MIC for 24 h in nutrient growth conditions employing a serial passage 
mutagenesis assay described previously.58, 59 The assay was repeated by propagating the 
bacteria exposed to the highest concentration of particles that did not inhibit growth. An 
illustrative overview of the serial passage mutagenesis assay is shown in Figure 4.3. After 
the completion of 20 passages of NO exposure in this manner, no sustained increases in 
the MIC for any of the bacterial species were observed versus the parent strains (Table 
4.2). The two-fold increase in susceptibility observed for S. aureus and S. epidermidis 
was not significant and is considered normal inter-experimental variation. 
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Figure 4.3. Illustrative overview of the serial passage mutagenesis assay. 
 
 
 
 
 
 
x/4 xx/2
[NO]
x/4 xx/2
[NO]
MIC
2 × 106 cfu/mL
Bacterial stock
NO exposurePropagation 24 h
37 °C
116 
 
 
 
 
 
 
 
 
 
 
Table 4.2. Minimum inhibitory concentrations of 75 mol% MTPMS/TEOS particles after 
1 and 20 passages in 1 × 106 cfu/mL bacterial stock. 
 
 
 
 
 
 
 
 
MIC24h (mg mL-1)
species ATCC # Day 1 Day 20 ΔMIC
S. aureus 29213 3.13 3.13 0
MRSA 33591 3.13 1.65 -50%
S. epidermidis 35983 6.25 3.13 -50%
E. coli (0157:H7) 35150 6.25 6.25 0
P. aeruginosa 19143 6.25 6.25 0
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4.4 Conclusions 
The inability of bacteria to develop resistance to exogenous NO delivered from a 
silica vehicle was not surprising primarily because of the multiple mechanisms by which 
NO presents toxicity towards microbes.2, 9, 12, 13, 16, 48 The hydrophobicity and small size 
of NO allows it to rapidly migrate across bacterial lipid membranes where a number of 
nitrosative and oxidative reactions may occur (Figure 4.4).13 The diversity of NO’s 
antimicrobial mechanisms thus would require multiple mutations to occur simultaneously 
for microbial survival, hindering resistance development. Nevertheless, it would be naïve 
to conclude that bacteria absolutely cannot develop increased resistance to exogenous 
NO. Spellberg et al. points out the fallacy of assuming that we (humans) can win a war 
against bacteria that have been “creating and defeating antibiotics for 20 million times 
longer than Homo sapiens have known that antibiotics existed.”63 It is likely that the 
emergence of resistance to exogenous NO will depend heavily on environmental 
conditions such as nutrient availability, temperature, exposure duration/intensity, the 
presence of other bacterial species, and infection location (i.e., in vivo vs. in vitro). 
Clearly, it is imperative that future studies examining the efficacy of NO-releasing 
therapeutics also consider the ability of bacteria to develop resistance, especially as such 
therapeutics are applied clinically. 
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Figure 4.4. Illustration of nitrosative and oxidative antimicrobial mechanism of NO 
within a bacterial membrane. Reprinted with permission from ref. 13. Copyright 2008 
American Chemical Society. 
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Chapter 5 
Microfluidic Nitric Oxide Sensor for Biological Applications 
 
Introduction 
Few endogenously produced small molecules are involved in such expansive roles 
as nitric oxide (NO), a diatomic free-radical. Since being identified in 1987 as the 
endothelium-derived relaxation factor responsible for regulating vascular tone,1-3 NO has 
been the subject of intense scientific interest. Nitric oxide is generated through the 
conversion of L-arginine to L-citrulline by a class of enzymes known as nitric oxide 
synthases (NOS).4-8 Two constitutive isoforms of NOS, neuronal and endothelial NOS, 
produce NO at pM to nM concentrations in physiological milieu.9, 10 The inducible NOS 
isoform, iNOS, expressed by phagocytes during immune system activation, results in 
much greater NO concentrations (e.g., >10 µM in blood).11, 12 Nitric oxide has also been 
implicated in other physiological processes including wound healing,13-15 angiogenesis,16-
19 and the inhibition of platelet activation.20-22 As might be expected, the detection and 
quantification of NO has been and continues to be the subject of intense research.23-27 
Measuring NO in biological systems is challenging due to NO’s reactivity (i.e., 
short half-life), wide concentration range (pM–10 µM), and sample (i.e., matrix) 
complexity.23 Despite these challenges, both direct and indirect analytical methods have 
been developed for measuring NO in biological samples. Often, NO is more easily 
quantified by measuring specific oxidative byproducts (e.g., nitrite and nitrate). In this 
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respect, absorbance or fluorescence may be used upon reaction of NOx with an assay 
reagent.12, 28-30 Indeed, the Griess assay is the most widely used approach for measuring 
NOx and back-calculating NO levels. Unfortunately, NOx levels fluctuate significantly 
due to diet and other underlying diseases and thus make real-time NO concentration 
determination in complex media nearly impossible. Alternatively, methods for measuring 
NO directly include chemiluminescence,31, 32 electron paramagnetic resonance (EPR) 
spectroscopy,24, 31, 33 and electrochemistry.26 Although direct measurement allows for 
sensitive and selective NO detection, chemiluminescence and EPR instrumentation is 
expensive, specialized, and often difficult to adapt to challenging matrices such as whole 
blood.26 
Among the direct detection methods, electrochemistry is the most straightforward, 
inexpensive, and versatile for measuring NO, with a large assortment of available sensor 
platforms (i.e., sensor style, geometry, material, and size).23, 24, 26, 27, 33-48 In terms of 
clinical utility, electrochemical sensors are highly amenable to miniaturization, thus 
enabling in vivo and ex vivo measurements.23, 24, 49, 50 One obstacle for measuring NO 
accurately in biological milieu is interfering species such as nitrite, acetaminophen and 
ascorbic acid,23 and thus almost all effective NO sensor designs include a membrane to 
reduce the diffusion of such interferents to the working electrode. For example, Teflon®, 
Nafion®, and silicon rubber (SiR) membranes restrict the diffusion of anionic nitrite and 
larger molecules relative to NO.42, 44, 50, 51 While these membranes are effective at limiting 
a select group of interferences, such membranes do not enable selectivity over all of the 
interfering species encountered in vivo. We recently reported the synthesis of fluorinated 
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xerogel sensor membranes capable of excluding nitrite, acetaminophen, ascorbic acid,  
uric acid, ammonia, and dopamine, even at high concentrations (i.e., 100 µM).45  
The style of electrode platform (i.e., needle-type, planar, microfluidic) is often 
dependent on the intended measuring environment. Planar macroelectrodes provide 
excellent sensitivity to NO, but only when large volumes of sample fluid are available. 
For small sample aliquots (<1 mL), miniaturized sensors are necessary.41, 47 To measure 
NO intravascularly, Malinski et al. fabricated a Teflon-coated NO microsensor that was 
able to track NO in the blood stream of humans in real time before and after the 
administration of bradykinin.47 Unfortunately, the clinical success of intravascular 
sensors is hindered by biofouling (i.e., protein adsorption, platelet adhesion, and clot 
formation), limiting sensor lifetime to only a few hours. While ex vivo measurements are 
possible, most current sensor designs require a stirred solution that introduces noise and 
demands large sample volumes (>1 mL). 
In contrast to standalone sensors, microfluidic technology allows for reduced 
sample volume and minimal sample handling, and thus address many of the shortcomings 
of existing analytical methodology required in clinical settings.52, 53 With respect to NO, 
Spence et al. used microfluidics to measure NO from stimulated endothelial cells with a 
planar carbon ink electrode fabricated within a polydimethylsiloxane (PDMS)-based 
microfluidic channel.54 An unfortunate caveat of using hydrophobic PDMS for 
microfluidic channel fabrication is an inaccurately low measurement since gases readily 
diffuse through PDMS.54 Recognizing this problem, Cha et al. reported the fabrication of 
a catalytic gold/indium tin oxide microfluidic NO sensor with non-NO-permeable 
polyethylene tetraphthalate/polyurethane channels, thus minimizing NO loss.55 Of note, 
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the design and necessary hand-assembly of this device is not amenable to larger-scale 
production made possible by photolithographic microfabrication.   
Herein, we report the fabrication of a microfluidic NO sensor using standard 
photolithographic techniques amenable to rapid and inexpensive fabrication. The 
analytical performance of the device in phosphate buffered saline (PBS) make it ideal for 
measuring NO in small volumes of complex biological matrices at low concentrations.  
 
5.2 Materials and Methods 
 (Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane (17FTMS) was 
purchased from Gelest (Tullytown, PA). Methyltrimethoxysilane (MTMOS), ascorbic 
acid, acetaminophen, and sodium nitrite were purchased from Sigma (St. Louis, MO). 
Nitric oxide (99.5%), nitrogen, and argon gases were obtained from National Welders 
Supply (Raleigh, NC). Other solvents and chemicals were analytical-reagent grade and 
used as received. A Millipore Milli-Q UV Gradient A10 System (Bedford, MA) was used 
to purify distilled water to a final resistivity of 18.2 MΩ·cm and a total organic content of 
<6 ppb. Whole porcine blood was obtained in 1:10 EDTA from healthy pigs at the 
Frances Owen Blood Lab (University of North Carolina, Chapel Hill, NC). 
5.2.1 Preparation of working electrodes. Planar platinum (Pt) electrodes were 
fabricated on a glass substrate via photolithography and evaporative metal deposition. 
Glass substrates (4 × 4 in) were cleaned with distilled water, isopropanol, N2, and then 
dried on a hotplate at 95 °C for 5 min. After cooling to RT, photoresist (Microposit 
S1813, Microchem Corp., Newton, MA) was deposited via spincoating at 3000 rpm for 
45 s and then soft-baked at 115 °C for 2 min. The electrode pattern was exposed through 
a mylar mask for 10 s using a Karl Suss MA6/BA6 mask aligner (hard contact, 100 µm 
129 
 
gap) equipped with a 350 W UV lamp. The pattern was developed in an AZ400 alkaline 
developer for 1 min, thoroughly rinsed with distilled water, dried with N2, and post-baked 
on a hotplate at 115 °C for 2 min. To form a recessed electrode region, the exposed glass 
was etched in buffered oxide etch (BOE) to a depth of ~150 nm, then rinsed in distilled 
water and dried with N2. The exposed glass surface was further cleaned in an oxygen 
plasma at 100 W for 1 min. To form the electrodes, 10 nm Ti and 150 nm Pt were 
deposited in a magnetron sputterer. The substrate was soaked in acetone to liftoff the 
remaning photoresist and excess metal, resulting in patterned electrodes on the glass 
substrate. 
5.2.2 Electrode characterization. To evaluate the sensitivity of the NO sensors, 
amperometric measurements were performed using a CH Instruments 700 B 8-channel 
potentiostat (Austin, TX). The electrochemical cell consisted of a microfabricated planar 
Pt working electrode, an Ag/AgCl reference electrode, and a coiled Pt wire counter 
electrode.  
A saturated NO solution (1.9 mM) was prepared as described previously by 
purging phosphate-buffered saline (PBS; 0.01 M, pH 7.4) with Ar for 30 min to remove 
oxygen. Nitric oxide (99.5%) was then bubbled through this solution for at least 30 min.45 
The NO gas was purified before use by passing it a column with KOH pellets to remove 
trace NO degradation products. Glass substrates containing the sensors were diced into 4 
sections, each containing 16 electrodes. The connections between the electrodes and 
solder-on pads were insulated with S1813. Wires were soldered to the connection pads to 
allow connection to the potentiostat. The electrodes were polarized at +0.7 V in a stirred 
solution of PBS until a steady background current was attained (>1 h). Nitric oxide 
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sensitivity was measured by injecting sequentially increasing aliquots of a saturated NO 
solution into the PBS, resulting in a measured change in oxidation current. Background 
noise was measured as the standard deviation of the background current measured at each 
electrode before injection of NO. 
5.2.3 Membrane synthesis and deposition. Working electrode-modified glass 
substrates were rinsed with distilled water, dried with N2, and heated to 95 °C for 5 min. 
After cooling, an adhesion layer of MTMOS was deposited by spin-coating 3 mL of a 1:3 
(v:v) dilution of MTMOS in ethanol onto the substrate at 3000 rpm. The 
fluoroalkoxysilane membrane solution was synthesized via the acid catalyzed hydrolysis 
and condensation of 17FTMS and MTMOS as reported previously.45 Absolute ethanol 
(600 µL), MTMOS (120 µL), 17FTMS (30 µL), distilled water (160 µL), and 0.5 M HCl 
(10 µL) were added sequentially to a 1.5 mL microcentrifuge tube, mixing vigorously 
between the addition of each component, and then vortexed for 1 h. Working in 16 
electrode batches, 100 µL of the sol solution was pipetted across the working electrodes, 
and then tilted gently in all directions for 90 s to ensure even coating. The membrane 
solution was quickly dried by spinning at 600 rpm for 1 min. The xerogel was dried 
overnight in ambient conditions to facilitate adequate curing. This process was then 
repeated for the remaining electrodes. Membrane thicknesses were characterized with a 
profilometer (P15, KLA-Tencor Corp., San Jose, CA). 
5.2.4 Microfluidic device fabrication. Reference electrodes were fabricated on the 
substrate with the working and counter electrodes. The substrate was cleaned, patterned 
with S1813 photoresist, and plasma-treated as described above. To fabricate reference 
electrodes, 20 nm Ti and 1.5 µm Ag was deposited in a magnetron sputterer. The 
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substrate was soaked in acetone to liftoff the remaning photoresist and excess metal, 
resulting in patterned Ag electrodes. Pseudo-reference electrodes were formed via 
chemical oxidation of the Ag electrodes by reaction in 50 mM FeCl2 for 15 s, followed 
by thorough rinsing with distilled water. To form channel walls and insulate electrode 
connections, KMPR® 1010 was patterned on the substrate. Briefly, KMPR was deposited 
twice via spin-coating at 500 rpm for 10 sec and 1500 rpm for 45 sec. The substrate was 
soft-baked at 100 °C for 5 min, exposed to UV light through a mylar mask for 15 sec, and 
then developed in SU-8 developer for 4 min. After rinsing with distilled water, the 
substrate was dried with N2, and hard-baked at 150 °C for 10 min. To complete the 
assembly of the device, a glass microscope slide with pre-drilled inlet and outlet vias was 
used as the top lid. A thin layer of KMPR was spin-coated onto the glass slide at 3000 
rpm for 45 sec and soft-baked for 5 min at 100 °C to bond the glass slide to the KMPR 
patterned on the bottom substrate,. The glass slide was then fusion-bonded onto the 
bottom substrate by clamping the components together with spring clamps and baking at 
100 °C for 1 h. The ends of the channel were sealed and 8 mm dia inlet/outlet reservoirs 
were affixed using a high-strength, chemical-resistant epoxy (Hysol E-120HP; Henkle 
Corp., Morrisville, NC). Electrical wires were soldered directly to the solder-on pads of 
each electrode, facilitating an electrical connection. 
5.2.5 Microfluidic device characterization. To evaluate the performance of the 
microfluidic device, the working, counter, and reference electrodes were connected to a 
CH Instruments 1030A 8-channel potentiostat. By attaching a 1.5 inch length of tygon 
tubing to the inlet reservoir and filling it with PBS, flow was maintained by gravity alone 
at a rate of 15 µL/min. The device was polarized for up to 1 h at +0.7 V vs. the AgCl 
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pseudo-reference electrode by flowing PBS into the device. To calibrate the device, 
solutions of deoxygenated PBS containing increasing concentrations of NO were added 
to the sample reservoir. To assess the selectivity of the device, solutions of nitrite, 
acetaminophen, and ascorbic acid (100 µM in water) were added to the sample reservoir. 
The sensitivity of the microfluidic device was tested in both anticoagulated whole blood 
(5 mM EDTA) and simulated wound fluid (10% v/v fetal bovine serum in water). 
Saturated NO solution was added to 1 mL aliquots of blood and wound fluid, mixed 
briefly, and added to the sample reservoir. To maintain a flow rate of 15 µL/min when 
using whole blood, a small vacuum via was applied at the device outlet using a venturi 
pump. 
 
5.3 Results and Discussion 
5.3.1 Working electrode fabrication and characterization. Several types of 
microfabricated working electrodes have been utilized for NO sensing.45, 46, 54, 55 For 
example, Spence and coworkers employed a carbon ink electrode deposited in a PDMS 
channel and coated with Nafion for selectivity over nitrite.54 Cha et al. utilized a catalytic 
gold-hexacyannoferrate layer on a gold/indium tin oxide electrode coated with a gas-
permeable membrane as their selective working electrode.55 The Schoenfisch lab has 
successfully utilized platinum electrodes for NO sensing via multiple electrode 
platforms.45, 46 To simplify the microfabrication process and avoid the use of carbon inks 
or catalytic layers, platinum electrodes were employed in this study. Microfabricated NO 
electrodes were fabricated using standard photolithographic techniques and metal 
evaporation, resulting in 150 nm thick Pt electrodes as measured by a quartz crystal 
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microbalance. An intermediate 10 nm layer of Ti was added between the glass and Pt 
layer to improve adhesion of the electrode to the glass surface. The working electrodes 
were also recessed ~150 nm into the glass substrate via buffered oxide etch (BOE) 
etching prior to metal evaporation, thus ensuring successful liftoff of excess metal during 
the fabrication. The general design for the electrode pattern is illustrated in Figure 5.1. To 
fully elucidate the effect of electrode surface area on the sensitivity and background, 
electrode widths were varied from 50–1000 µm. The sensitivity of the electrodes was 
characterized via amperometry in stirred PBS (pH 7.4) by adding aliquots of a saturated 
NO solution (1.9 mM). As expected, the sensitivity of each electrode scaled linearly with 
electrode surface area (Figure 5.2). Nitric oxide sensitivity ranged from 0.94 pA/nM for 
the 50 µm wide Pt electrodes to 17.3 pA/nM for the 1000 µm wide electrodes. 
Background noise (RMS) also scaled linearly with electrode surface area from 43.2 to 
301 pA for the 50 µm and 1000 µm wide electrodes, respectively. Noise for the bare 
electrode was relatively high, resulting in limits of detection (LOD) ranging from 80-277 
nM NO. However, much of the background noise was attributed to inductive coupling of 
the magnetic stir plate to the planar electrodes, fluctuating PBS levels during convection, 
and/or lack of a selective membrane.   
A commonly employed strategy for enhancing the sensitivity of bare Pt electrodes 
for NO is platinization, where the electrodeposition of Pt black results in a rough Pt 
surface with greater surface area.45 Platinization may be performed by cycling the 
potential of a Pt electrode immersed in chloroplatanic acid. The deposition of Pt black on 
the electrode occurs via a 3 step, 8 electron process outline in Scheme 5.1.56  As 
expected, platinization of the microfabricated planar Pt electrodes did enhance the 
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sensitivity to NO in a stirred solution of PBS. However, noise levels were also increased 
drastically for the larger electrode widths (≥500 µm), resulting in poor LOD for NO. The 
LOD for electrodes with widths <500 µm was lower for platinized electrodes, 
demonstrating that modification of electrodes with Pt black would potentially benefit 
smaller electrodes. A comparison of the sensitivity and LOD for bare and platinized 
sensors of select widths is provided in Table 5.1. Platinization was not utilized further for 
this study because of the noise introduced at each electrode. However, the strategy may 
be utilized for future versions of the NO electrodes if additional sensitivity enhancement 
is required.  
 5.3.2 Membrane deposition and characterization. To ensure adequate selectivity 
for NO over interfering species and reduce background noise, a fluorinated alkoxysilane 
xerogel membrane (20% 17FTMS-MTMOS) was deposited over the microfabricated 
electrodes. We previously reported the high selectivity obtainable using 17FTMS 
membranes when applied via dip-coating to platinum-modified tungsten conical wire 
electrodes.45 Of note, this coating method was not feasible for the microfabricated planar 
Pt electrodes as selective and consistent deposition on only the electrode surface could 
not be adequately controlled. Instead, a combination of spread and spin-casting were 
employed. Application of a negative photoresist (S1813) mask was first utilized to allow 
for selective deposition of the membrane solution over the working, but not the counter 
and reference electrodes. 
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Figure 5.1. Illustration of a Pt working electrode pattern on a glass substrate. 
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Figure 5.2. The effect of working electrode width on sensitivity to NO (R2 = 0.99). 
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Scheme 5.1. Electrochemical platinization reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PtIVCl62- + 2e- PtIICl42- + 2Cl- (1) 
PtIICl42- + 2e- Pt  + 4Cl- (2)
PtIVCl62- + 4e- Pt + 6Cl- (3) 
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Table 5.1. Electrode sensitivity and limit of detection for NO as a function of widths 
between bare platinum (Pt) and platinum-black-coated (PtB) electrode. 
 
 
 
 
 
 
 
 
 
 
 
Sensor width
75 µm 100 µm 500 µm 1000 µm
Pt PtB Pt PtB Pt PtB Pt PtB
Sensitivity (pA/nM) 1.9 6.3 2.2 5.7 6.1 11 17 26
Limit of Detection (nM) 200 38 260 60 312 820 337 2400
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After allowing some of the ethanol to evaporate, thus increasing the solution viscosity, 
the substrate was spun at 600 rpm to remove excess xerogel solution. Initial testing 
showed that the ethanol present in the membrane solution slightly dissolved and mixed 
with the photoresist. As such, S1813 that had incorporated into the xerogel was dissolved 
during liftoff of the photoresist mask, weakening and cracking parts of the xerogel 
membrane. Nevertheless, enough of the xerogel membrane remained intact to allow for 
preliminary testing of an assembled microfluidic device. A second method of deposition 
was later employed to avoid problems encountered with the ethanol compatibility of the 
S1813 photoresist. In this method, the counter and reference electrodes were deposited 
onto the lid of the microfluidic device rather than on the same substrate as the working 
electrodes to avoid the need for a photoresist mask for the xerogel. Spread casting was 
utilized to deposit the membrane solution, and the substrate was tilted slightly in all 
directions to evenly coat the electrodes. This technique ensured that a precise volume of 
sol solution was deposited on the substrate, resulting in consistent average thicknesses of 
500 nm over each electrode as determined by profilometry. The effectiveness of both 
membrane deposition strategies are discussed below. 
Characterization of with respect to sensitivity and selectivity was carried out in a 
stirred solution of PBS to confirm that the membrane allowed adequate sensitivity to NO 
and selectivity over interfering species. One immediate benefit of the NO-selective 
membrane was significant noise reduction observed for non-platinized electrodes. 
Although the sensitivity of the membrane-coated electrodes was reduced slightly (2.2 to 
2.0 pA/nM NO for 100 µm and 17 to 13 pA/nM NO for 1000 µm electrodes), the 
decreased noise resulted in improved LOD. For example, the LOD observed with the 
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fluorinated membrane at the 100 and 1000 µm electrodes was reduced by 97 % (260 to 6 
nM NO) and 94% (337 to 21 nM NO), respectively. Interestingly, membrane-coated 
platinized electrodes were characterized by a slow response to NO and significant signal 
drift. For this reason, platinization was not utilized further to enhance NO electrode 
sensitivity. 
The selectivity of the membrane-coated electrodes for NO over nitrite, ascorbic 
acid, and actetaminophen was evaluated in a stirred PBS solution. Interferent 
concentrations used in the study were chosen to be well in excess of the expected 
physiological concentrations. As expected, the sensitivities of the 100 and 1000 µm 
electrodes to NO were ~4 orders of magnitude greater than the sensitivities for the 
interferents, with the exception of ascorbic acid, where the NO response was only ~2.5 
orders of magnitude greater than the interferent for the 1000 µm electrodes. 
5.3.3 Reference electrode fabrication and characterization. Due to the small size 
of the microfluidic channel, a traditional solution-based Ag/AgCl reference could not be 
utilized for this device. Many groups have utilized wire pseudo-reference electrodes in 
the construction of microfluidic sensors. For example, Spence et al. placed a Pt quasi 
reference electrode at the solution outlet of their PDMS-based NO measurement device.54 
However, this design was found to be practical only if the distance between the electrode 
and the outlet reservoir is small enough to minimize electrical resistance. Cha et al. 
utilized an oxidized silver wire pseudo reference electrode inserted next to the working 
electrode in the channel, although this approach required careful hand positioning of the 
electrode during fabrication.55 More precise positioning and integration of reference 
electrodes may be attained via microfabrication of the reference electrode within the 
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microfluidic channel. Typically, this may be achieved by first depositing a silver 
electrode, and then chemically or electrochemically oxidizing the surface. For example, 
Heuck and Staufer reported the deposition of silver within a microfluidic channel using a 
Tollens reagent, where aqueous silver was chemically precipitated onto glass, followed 
by chemical oxidation with ferric chloride.57 To attain a thick enough silver layer to 
prevent disintegration of the electrode during oxidation, multiple deposition steps were 
necessary, requiring large volumes of the potentially explosive Tollens reagent. Polk et 
al. pursued an alternative strategy involving evaporative deposition of the silver 
electrode.58 Specifically, a substrate with 150 nm thick Ag electrodes was patterned via 
evaporative deposition. The thickness of the Ag electrodes was increased to 1–5 µm via 
electroplating, followed by chemical oxidation with ferric chloride. While the electrodes 
were found to be stable for up to 4 d of continuous use, the measured potentials were not 
uniform among the entire batch of electrodes, likely owing to inconsistent 
electrochemical plating.  
To simplify the process of reference electrode fabrication, thick films of Ag (~1.5 
µm) were deposited onto a thin (10 nm) Ti adhesion layer. Two negative photoresist 
layers, a liftoff resist (LOR) bottom layer and S1813 top layer, were used to pattern the 
electrodes (Figure 5.3B). The use of the additional LOR layer resulted in undercutting of 
the S1813 photoresist. After deposition of the silver layer, the undercut photoresist 
prevents a connection of the thick silver layer between the electrodes and the excess 
silver deposited around the electrodes that may result in “dog ears” after liftoff (Figure 
5.3A) and peeling of the electrode. To further protect the Ag electrodes from peeling, 
buffered oxide etch (BOE) was utilized prior to metal deposition to form 1.5 µm deep  
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Figure 5.3. Cutaway illustration of reference electrode profile after masking and Ag 
deposition using A), an S1813 mask only, resulting in “dog ears” after liftoff, and B), a 
mask composed of both LOR and S1813. 
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troughs where electrodes could be deposited. The Ag electrodes were then oxidized with 
ferric chloride prior to assembly of the chip (rather than within the microfluidic channel) 
to prevent over-oxidation of the Ag by residual ferric chloride that would have been 
difficult to rinse out of the channel completely. 
5.3.4 Microfluidic device assembly. The microfluidic portion of the device was 
combined with the glass substrate after fabrication of the membrane-coated working 
electrodes, Pt counter electrodes, and Ag/AgCl working electrodes. Initially, double-
sided Kapton® polyimide tape was utilized to form the walls of the microfluidic channel 
and facilitate attachment of a glass slide as a lid of the channel. Two strips of tape were 
deposited 3 mm apart across the electrodes so that a portion of each electrode was 
exposed in the channel. A clean glass slide with via holes at both ends was affixed on top 
of the tape, forming the microfluidic channel. Flow testing of the device assembled with 
polyimide tape led to sporadic leakage on some devices. Use of the polyimide tape also 
resulted in imprecise positioning across the electrodes and difficulty maintaining 
consistent channel width. To ensure a more precise, leak-free microfluidic channel, a 
negative photoresist, KMPR, was patterned on the substrate. The KMPR served as both 
an insulator for the connections between the electrodes and solder-on pads, as well as 
walls for the microfluidic channel. By precisely controlling spin speed and employing 
two KMPR depositions, a 40 µm deep, 3 mm wide channel was formed across each set of 
electrodes (Figure 5.4). A KMPR-coated glass slide with pre-drilled vias was used as the 
lid of the microfluidic channel. The KMPR on the glass slide was coated on the underside 
and not exposed with UV prior to assembly, thus allowing fusion bonding to the KMPR 
deposited on the electrode substrate with only moderate mechanical pressure and heat. 
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The resulting channel was leak-free upon flow testing and maintained a consistent width 
across the device. Although only one channel depth and width was utilized for initial 
studies, flow rate may be controlled by adjusting either parameter. A deep, wide channel 
was chosen for this design to allow for adequate flow of more viscous biological fluids 
(e.g., blood and plasma). Hard plastic 8 mm diameter reservoirs attached with epoxy over 
the inlet and outlet vias provided a means of adding fluids to and removing waste from 
the microfluidic device (Figure 5.5). A section of tubing attached to the inlet reservoir 
provided adaquate pressure when filled to drive flow at ~15 µL/min without the need for 
an external vacuum pump. When using blood and plasma, a variable venturi pump was 
attached to the outlet via and adjusted to provide a ~15 µL/min flow rate. A photograph 
of the final microfluidic device with the reservoir tubing installed is shown in Figure 5.6. 
5.3.5 Microfluidic device characterization. To characterize performance of the 
microfluidic NO sensor, the sensitivity and selectivity of the device was tested using 
constant potential amperometry at a potential of +0.7 V vs. The electrode was polarized 
in PBS for at most 1 h prior to testing to achieve a steady baseline current. Nitric oxide 
calibration curves were constructed by adding aliquots of saturated NO to a deoxygenated 
PBS solution and transferring a small quantity of this solution to the reservoir of the 
device.   
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Figure 5.4. Cutaway illustration of microfluidic channel construction. 
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Figure 5.5. Top-view illustration of microfluidic device with placement of inlet and outlet 
reservoirs. 
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Figure 5.6. Photograph of the microfluidic device with attached sample reservoir. 
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After the oxidation current stabilized, the NO solution in the reservoir was removed and 
replaced with a more concentrated NO solution. The real-time NO addition and the NO 
calibration plot is shown for a 100 µm bare and membrane-coated electrode in Figure 5.7. 
The sensitivities of the bare and membrane-coated electrodes were measured to be 2.7 
and 2.3 pA/nM NO, respectively. As expected, the membrane-coated electrode had a 
slightly lower sensitivity than the bare electrode due to reduced NO diffusion across the 
membrane to the electrode surface. The sensitivities for both the bare and coated 
electrodes were lower for the microfluidic vs. non-microfluidic device because the 
channel exposes only a portion of the actual electrode area. Despite lower sensitivities, 
the LODs for both the bare and coated microfluidic electrodes were 590 and 760 pM, ~1 
log lower than the same electrodes outside of the microfluidic device. The improvement 
in the LOD is attributed to lower noise as a result of no convection and/or the elimination 
of the oscillating magnetic field from the magnetic stir plate. Furthermore, the flow 
provided to the microfluidic device is driven by either gravity or a venturi pump, 
preventing the pulsatile noise often encountered for syringe or peristaltic pumps. The 
selectivity of the microfluidic device over the most common interfering species (i.e., 
nitrite, acetaminophen, and ascorbic acid) is shown in Figure 5.8. While the bare 
electrode registered a slight response from nitrite and greater responses from 
acetaminophen and ascorbic acid, (selectivities of -5, -2.3, and -2.6, respectively), the 
response from nitrite was undetectable and only slightly detectable for acetaminophen 
and ascorbic acid (<-6, -4.3, and -3.7, respectively) for devices employing the NO-
selective 17FTMS membrane.  
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Figure 5.7. Response of bare (gray line) and membrane-coated (black line) microfluidic-
based NO sensors to NO in PBS flowing at 15 µL/min. Inset shows NO calibration 
curves for bare (●) and membrane-coated (■) sensors. 
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Figure 5.8. Response of bare (dotted line) and membrane-coated (solid line) microfluidic-
based NO sensors to interfering species in PBS flowing at 15 µL/min.  
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5.3.6 Microfluidic NO sensor response in physiological fluids. Since the intended 
purpose of the microfluidic NO sensor is the detection of NO in biological fluids, the 
microfluidic NO sensor was next characterized in whole blood and wound fluid, two 
matrices where NO measurements are clinically useful yet difficult. Indeed, measurement 
of NO in blood is particularly challenging because of the presence of NO scavengers such 
as hemoglobin and oxygen. To characterize the sensor response in whole blood, aliquots 
of an NO solution were added to measured volumes of blood, mixed, and then added to 
the microfluidic NO sensor where NO was detected at +0.7 V vs. Ag/AgCl. The time 
elapsed from the injection of NO into the blood aliquot to the addition of the blood to the 
device did not exceet 10 s. Since blood is more viscous than PBS, a venturi pump was 
used at the channel outlet to provide a constant flow rate of 15 µL/min. As shown in 
Figure 5.9, clean blood was initially flowed into the device, followed by blood aliquots 
with NO concentrations increasing by 5 µM, resulting in detectable and consistent 
increases in the magnitude of the oxidation current due to NO measured at the working 
electrode. Upon adding clean blood into the microfludic NO sensor, the current returned 
to the original baseline level. Although the sensitivity for NO in blood was decreased 
compared to PBS (56 pA/µM NO in blood vs. 2.3 pA/nM NO in PBS), the reduced noise 
inherent to the microfluidic sensor reduced the LOD to a biologically-reasonable level of 
225 nM. To test the practical lower NO concentration limits of the device, NO 
concentrations in blood were changed in 500 nM increments (Figure 5.10). In doing so, 
the sensitivity range of the potentiostat was reduced, resulting in a lower calculated LOD 
for NO in blood (~50 nM). The resulting LOD of 50 would be well below the required 
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LOD needed for detecting NO in blood during sepsis, for example, where NO 
concentrations have been reported to exceed 10 µM.11, 12, 59  
Since NO is believed to be a potential prognostic biomarker for wound healing 
progress,13-15, 60 the operation of the microfluidic NO sensor was also tested in simulated 
wound fluid (10% fetal bovine serum in water) (Figure 5.11). The resulting LOD was 2 
nM, 1-2 orders of magnitude lower than in blood, attributable to the absence of 
scavenging from blood proteins and hemoglobin. 
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Figure 5.9. Response of membrane-coated microfluidic-based NO sensor to 5 µM 
increases of NO concentrations in whole blood flowing at 15 µL/min.  
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Figure 5.10. Response of membrane-coated microfluidic-based NO sensor to various 
concentrations of NO in whole blood flowing at 15 µL/min. 
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Figure 5.11. Response of membrane-coated microfluidic-based NO sensor to 50 nM 
increases of NO concentrations in 10% FBS flowing at 15 µL/min. 
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5.4 Conclusions 
 The use of a selective fluorinated membrane in combination with an 
electrochemical microsensor within a microfluidic device enables highly sensitive 
detection of NO in challenging biological matrices such as blood and simulated wound 
fluid. In contrast to previously reported devices, the use of standard photolithographic 
microfabrication techniques makes the assembly highly amenable to rapid, large-scale 
production. The resulting microfluidic sensor was characterized by excellent sensitivity 
for NO in PBS, (2.3 pA/nM), and selectivity over interfering species (<-6, -4.3, and -3.7 
for nitrite, ascorbic acid, and acetaminophen, respectively). The low background noise 
levels of the electrochemical microfluidic device resulted in very low LODs for NO in 
PBS, blood, and simulated wound fluid (760 pM, 50 nM, and 2 nM, respectively). To 
date, the reported 50 nM LOD for NO in blood is the lowest reported for the direct 
electrochemical detection of NO.  Overall, unlike previous NO detection methods, this 
device provides a platform for quickly measuring NO directly at very low concentrations 
in small volumes of biological fluids.  
A number of possible applications exist that may be well served by this 
technology. In the field of skin wounds, the need for tools to assess the progress of 
wound healing and the efficacy of treatment is significant. Although the role of NO in 
wound healing has been studied,61-64 the correlation between NO and prognosis (i.e., 
whether the wound will heal) is not well understood. The low LOD for NO in wound 
fluid may aide in more accurate measurement of NO during wound healing. Furthermore, 
this knowledge may provide a tool for better assessing treatment efficacy. Nitric oxide 
also plays an important role in the immune response to pathogens.12, 65, 66 Indeed, NO 
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concentrations >10 µM have been measured indirectly (using the griess assay) during 
clinical sepsis. By utilizing the microfluidic NO sensor to measure NO in blood, an 
improved evaluation of how NO levels change during sepsis may be undertaken. In 
addition, this device may enable an examination of NO as a potential biomarker for 
sepsis prognosis. 
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Chapter 6 
Summary and Future Research Directions 
 
6.1 Summary  
 The efficacy of superhydrophobic and NO-releasing surfaces, the fabrication and 
characterization of a microfluidic NO sensor, and the evaluation of bacterial resistance to 
exogenous NO was described in the preceding chapters. In Chapter 2, the efficacy of NO-
releasing xerogel surfaces against the pathogenic fungus C. albicans was evaluated using 
three adhesion and viability assays. In the first assay, a parallel plate flow cell was 
utilized to quantify cellular adhesion to the surfaces as a function of NO release. The 
adhesion of C. albicans to the coatings with the highest NO fluxes was reduced by 52% 
compared to control (non-NO-releasing) surfaces. The viability of the adhered fungus 
was characterized via nucleic acid staining in combination with fluorescence microscopy. 
Cell death was observed after 11 h of fungal exposure to the surface with the highest NO 
flux. The reduction in viability due to NO was confirmed using a quantitative viability 
assay where cells were adhered to control and NO-releasing substrates, incubated in PBS 
for 15 h, removed from the surface via sonication, and then enumerated via plating on 
nutrient agar. The viability of fungal cells exposed to the highest flux of NO was reduced 
by 42% versus cells exposed to the lowest flux of NO. Biofilms of C. 
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albicans often result after initial adhesion to a surface and are notoriously difficult to 
treat. Thus, the efficacy of the NO-releasing xerogels against biofilm development was 
studied by incubating NO-releasing and control surfaces in a bacteria/nutrient broth 
suspension for 2 d. Environmental scanning electron microscopy was used to interrogate 
these substrates; much less biofilm formation was observed at the NO-releasing surfaces. 
The amount of biofilm was reduced even further upon combining NO release with sub-
therapeutic doses of silver sulfadiazine.  
The synthesis of superhydrophobic surfaces composed of fluorinated silica 
colloids doped into a fluorinated xerogel was described in Chapter 3. The surface 
topography was assessed via both SEM and AFM, and revealed a coating composed of 
both micro- and nano-structured features. The resulting interface was characterized by 
having a static water contact angle of >165°. The coating was stable after no change in 
the static water contact angle of the coating was measured after 15 d of immersion in 
distilled water. Using a combination flow cell and sonication viability assay, the ability of 
the coating to resist the adhesion of P. aeruginosa and S. aureus was described in PBS. 
These superhydrophobic surfaces reduced the adhesion of both bacteria by ~2 orders of 
magnitude vs. control surfaces.  
Studies investigating the likelihood that exogenous NO release may foster the 
emergence of NO-resistance in bacteria were described in Chapter 4. Several gram-
positive and gram-negative bacteria species were exposed to both repeated sub-
therapeutic doses of NO (serial passage mutagenesis) and single bactericidal doses of NO 
(spontaneous mutagenesis) from NO-releasing nitrosothiol particles. No significant 
increase in NO resistance was observed for bacteria during the spontaneous mutagenesis 
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or the serial passage mutagenesis assays. While this study is by no means comprehensive 
in the types of NO-releasing materials and associated NO release kinetics available, it 
provides a blueprint for future testing of bacterial resistance to NO. 
  The fabrication and characterization of a microfluidic electrochemical NO sensor 
for physiological measurements was presented in Chapter 5. Using standard 
photolithographic methods, working, counter, and reference electrodes were patterned 
onto a glass substrate. Microfluidic channels were then positioned across the electrodes 
along with a lid with access ports to fabricate a device capable of selectively measuring 
NO in small sample volumes (< 1 mL). The device was characterized in PBS with a limit 
of detection (LOD) of 760 pM and >4 orders of magnitude selectivity for NO over 
common interfering species (e.g., nitrite, ascorbic acid, and acetaminophen). The ability 
to determine NO levels in whole blood and simulated wound fluid was demonstrated with 
LODs for NO of 50 and 2 nM, respectively, making it well suited for potential clinical 
measurements.  
 
6.2 Future research directions 
 Future studies related to the efficacy of NO-releasing surfaces against fungal 
adhesion, proliferation, and biofilm formation should focus on increasing the NO-release 
capabilities of these xerogels. To this end, Storm and Schoenfisch are developing 
methods to pre-modify the aminosilanes precursors prior to xerogel synthesis and 
deposition, thus maximizing the amount of NO available for release.1 By increasing the 
NO release rate and amounts, it is hypothesized that the bactericidal efficacy would be 
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further enhanced. A study is also planned to utilize the enhanced permeability afforded 
by the pre-NO-modified coating for electrochemical glucose sensor membranes. It has 
been previously demonstrated that NO release reduces fibrous encapsulation and enhance 
angiogenesis surrounding implants.2-5 Thus, NO-releasing glucose sensor membranes 
may enhance the clinical utility of implanted glucose sensors by increasing glucose 
delivery and diffusion to the electrode.  
Future studies related to fluorinated silica colloid-based superhydrophobic 
coatings should be aimed at improving the scratch-resistance and robustness of the 
coatings on a variety of surfaces including glass, polymers, and metals. Development of 
the coatings for use on medical devices would necessitate in vivo biocompatibility studies 
where coated implants are intentionally seeded with bacteria. Studies in our lab are 
currently planned to evaluate the antimicrobial efficacy of superhydrophobic surfaces in 
combination with surface-released NO. By doping NO-releasing nanoparticles into the 
superhydrophobic coating,6-9 NO-releasing superhydrophobic surfaces may be possible. 
The combination of NO release with a superhydrophobic surface may more significantly 
enhance antimicrobial efficacy by killing any microbes that do manage to adhere to the 
superhydrophobic surfaces. Future work should also explore the suitability of the 
superhydrophobic coatings for other applications including biofouling reduction on boat 
hulls,10 water distribution pipes,11 and anti-icing surfaces for aircraft.12  
  While no increased NO resistance was observed in the resistance assays for a 
select number of bacteria tested, it is well known that the development of resistance to 
antimicrobials depends on both the type of bacteria and the conditions of exposure (i.e., 
antimicrobial concentration and kinetics, growth conditions, time of exposure).13 Future 
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studies must thus focus on the evaluation of other NO-releasing materials that are being 
developed for possible clinical use, as well as expanding the range of microbial species 
utilized in the tests. Should an increase in NO-resistance be observed, genetic analysis 
should be undertaken to identify if DNA mutations or changes in RNA expression are 
responsible. Such information would be useful for optimizing NO-releasing therapeutics 
and identifying synergistic NO/drug combinations that would reduce the likelihood of 
developing further bacterial resistance.  
Lastly, the developed microfluidic electrochemical NO sensor should be further 
evaluated in real samples. Toward this end, future work will focus on the optimization of 
device parameters (e.g., electrode size, microfluidic geometry, and membrane thickness) 
to improve the sensitivity and selectivity of the device in biological matrices such as 
blood and wound fluid. Subsequent work should evaluate the capabilities of the device in 
determining the time course of NO in various physiological processes such as wound 
healing and sepsis. Studies are already planned to utilize the microfluidic NO sensor for 
measuring changes in NO concentration in a porcine sepsis model and evaluating the 
efficacy of NO measurements as a diagnostic and prognostic biomarker for sepsis. Nitric 
oxide may also be a useful biomarker for evaluating the progress of wound healing and 
associated treatments.14, 15 Future studies must be designed to understand the time course 
of NO during the stages of wound healing and during the course of therapeutic treatment. 
By varying the device fabrication parameters (i.e., microfluidic geometry, membrane 
composition, and electrochemical technique), the device may be utilized for measuring 
multiple analytes to give a better diagnosis. For example, by adding the ability to detect 
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nitrate, nitrate, nitrosothiols oxygen, glucose, and lactate, a field portable comprehensive 
diagnostic device may be fabricated. 
By making slight modifications to the device, the NO sensor could also be used to 
evaluate NO-releasing therapeutics such as nanoparticles, dendrimers, small molecules, 
and polymers. Results from a report in preparation by Hunter et al. demonstrate that 
electrochemical detection of NO is superior in terms of sensitivity to traditional NO 
measurement techniques (i.e., Griess assay and chemiluminescence), especially in 
complex nutrient broths and physiological milieu.16 By adapting the microfluidic NO 
sensor described in Chapter 5 to measure NO-releasing materials in situ, NO release in 
complex media may be accurately assessed. 
6.3 Conclusions 
 As the demand for implanted medical devices increases, the development of 
creative strategies for preventing microbial adhesion and proliferation on medical devices 
will be critical. Novel surfaces that release antimicrobials that are biocidal via multiple 
mechanisms (i.e., NO) may allow for more effective antimicrobial coatings that do not 
foster resistance. Passive strategies such as superhydrophobic coatings are particularly 
important because they do not foster antimicrobial-resistant microbes. In addition, 
superhydrophobic surfaces may be applied to solve other commercial problems such as 
preventing the fouling of marine hulls, water pipes, and condenser coils, and preventing 
condensation and ice buildup on optical and aircraft surfaces. The demand is also 
increasing for diagnostic tools that diagnose and monitor treatment progress of diseases. 
Sensors that measure NO, a biomolecule implicated in immune response to infection, 
170 
 
may play a key role in the diagnosis and prognosis of several conditions including sepsis, 
wound healing, cancer, and neurodisorders. By allowing measurements to be performed 
in small volumes of fluid, microfluidic NO sensors may enable more rapid bedside 
diagnosis. These devices may also serve as platforms for evaluating NO-releasing 
therapeutics in vitro and during clinical use. 
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